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Introduction 
I.1 Glioblastoma multiforme 
Gliomas include all primary central nervous system (CNS) tumours of glial origin. 
They account for more than 50% of all brain tumours and are by far the most 
common primary brain tumours in adults.1 Gliomas have their origin in different glial 
cell types, mainly astrocytes and oligodendrocytes. They can be divided into four 
grades according to different levels of aggressiveness and malignancy that are 
reflected in the World Health Organization (WHO) classification system. 
Ependymomas account for 10% of all gliomas and are mainly benign.2 
Oligodendrogliomas account for 10–30% of all gliomas and are mainly low-grade, 
partly transitioning to high-grade. Astrocytomas account for 60–70% of gliomas.3 
Pilocytic astrocytomas are classified as  WHO grade I; low-grade astrocytomas are 
listed as WHO grade II; anaplastic astrocytomas are classified as WHO grade III and 
glioblastomas as WHO grade IV. Glioblastoma multiforme (GBM), the most 
aggressive subtype, may develop de novo (primary GBMs) or by progressing from 
low-grade or anaplastic astrocytomas (secondary GBMs).4 GBM is associated with 
the worst prognoses, with a median survival rate of 12–18 months post diagnosis, 
even under the best available therapy.5 GBMs account for approximately 50% of all 
glial tumour types.6  
Malignant astrocytic gliomas are associated with a dismal prognosis because of their 
ability to infiltrate diffusely into the normal brain parenchyma.7 The invasive nature of 
cells plays an important role in the ineffectiveness of current treatment modalities. 
The cancer cells that remain after surgical therapy inevitably infiltrate the surrounding 
normal brain tissue and lead to tumour recurrence. The diffuse nature of GBMs is 
illustrated by the fact that after surgical resection, the residual pool of invasive cells 
gives rise to a recurrent tumour, which in more than 90% of cases develops 
immediately adjacent to the resection margin.8 Satellite lesions may also occur at a 
distance from the resection cavity and even in the contralateral hemisphere.9,10 The 
above-described aggressiveness and invasiveness, our poor understanding of 
molecular mechanisms and genetic heterogeneity lead to the poor outcome of GBM 
treatment. Standard therapy currently consists of surgery, radiation and 
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chemotherapy.11 As stated in the above, prognosis is dismal and, consequently, 
novel therapeutic targets are desperately needed. 
 
I.1.1 Malignancy criteria in GBM 
The ability of glioblastoma multiforme cells to infiltrate the sourrounding tissue is 
influenced by a number of factors accounting complex intracelluar and extracellular 
pathways, extracellular components and enzyme activity. The process of invasion 
includes increased synthesis and secretion of several proteases, which selectively 
degrade extracellular matrix (ECM) components. These proteases also play a role in 
establishing and maintaining a microenvironment that facilitates tumour-cell 
survival.12 
Glioma cell invasion is a complex and multistep mechanism involving a large array of 
molecules mediating cell-cell and cell–extracellular matrix interactions. These 
processes allow individual tumour cells to migrate into and invade healthy brain 
tissue even after macroscopic radical surgical resection of the tumour.13 
Tumour cells at the invasive front detach from the growing primary tumour mass, 
adhere to the ECM via specific receptors and locally degrade ECM components, 
creating a pathway for neoplastic cells to migrate into adjacent tissue. However, the 
unique histological pattern of invasion shown by primary brain tumours together with 
the unique composition of the brain ECM suggest that glioma-specific mechanisms 
might also be involved.14,15 
In primary brain tumours, many ECM components are up-regulated within both the 
tumour stoma and at the advancing edge of the tumour. Changes in these ECM 
components are belived to modulate brain tumour growth, proliferation and invasion, 
although in many cases little is known about specific interactions and detailed 
mechanisms.16 Glioma cells also disseminate along the myelinated fibre tracts of 
white matter, which results in the distant spread of tumour cells through the corpus 
callosum to the contralateral hemisphere.17 
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I.2 Extracellular matrix 
I.2.1 Structure and function of extracellular matrix  
Extracellular matrix (ECM) not only acts as a physical framework, but also exerts a 
profound effect on cell shape and behaviour, including cell adhesion, spreading, 
migration, proliferation and differentiation.18 ECM is involved in normal reparative 
processes, as well as in primary brain neoplasia.  
Cells stay in contact with the ECM via surface receptors.19 Signal transduction leads 
to the remodelling of the ECM, which influences changes in motility, the ability to 
migrate and proliferate, and the expression patterns of a number of proteins (e.g. 
integrins). This mechanism results in a very dynamic process of composition and 
decomposition of the ECM. The composition of ECM components varies in different 
tissue types, especially in comparison to normal brain and brain tumour tissue.20 
 
I.2.2 Extracellular matrix in normal brain tissue 
Neuronal cell populations are surrounded by various types of ECM molecules. The 
microenvironment is responsible for the tumour cells’ adhesive ability, which has a 
major influence on neuronal growth and development.21 The ECM influences 
numerous functions and processes in the brain. During development of the brain, the 
ECM plays an important role in the migration of glial and neuronal precursor cells, in 
cell proliferation, directional axonal growth and expression of synaptic structures.22  
A well-defined ECM comprises a true basement membrane, cerebral vascularization 
and the glial membrana limitans externa. The membrana limitans externa is a 
basement membrane that covers the entire cortical surface of the brain and also 
separates astrocyte foot processes from pial cells and the subarachnoid space.23 The 
cerebral vascular basement membrane that surrounds the blood vessels of the brain 
contains type-IV and type-V collagens, fibronectin, laminin, vitronectin, heparan-
sulphate and proteoglycans.  
Proteoglycans and glycosaminoglycans are abundant in the brain parenchyma. In the 
mature brain, chondroitin sulphate is located in the cytoplasm of some neurons and 
astrocytes and in myelinated and non-myelinated axon fibres.24,25 Both chondroitin 
sulphate and heparan sulphate are also present in the basement membrane.26 
Heparan sulphate is found as a membrane protein in synaptic vesicles, in the ECM of 
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the neuromuscular junction and in the basement membranes of Schwann cells.27,28 
Heparan-sulphate proteoglycans have been found to induce cell motility.29  
  
I.2.3 Extracellular matrix in brain tumours 
We are gaining an increasing understanding of the decisive role which the ECM 
plays in repair processes and in the development of neoplasia.30 Major constituents 
of the ECM in brain tumours are proteoglycan, glycosaminoglycans and 
glycoproteins. 
Previous studies have already investigated changes in the composition of the ECM in 
normal brain compared to primary brain tumour tissue. It has been shown that tumour 
cell matrix has changing expression levels of HA and other glycosaminoglycans as 
well as osteopontin, vitronectin, tenascin-C and thrombospondin, depending on their 
localization on the blood vessel walls.31 Glycosaminoglycans are found mainly in 
brain tumour tissue. Their hyaluronic acid content is shown to increase transiently 
during tumour-cell migration and is usually found at the interface between the tumour 
mass and host tissues.32 Apart from its important role in tumour-cell invasion, 
hyaluronic acid is implicated in many normal cell functions, including neural-crest 
migration.33 Akiyama et al succeeded in showing that tumour-cell invasion and 
migration of primary brain tumours is mediated by the interaction of hyaluronan and 
cellular receptors called CD44 and RHAMM.34   
Fibronectin is found at the glioma–mesenchymal junction between tumours and in 
tumour-associated blood vessels, and it is expressed by glioblastoma cell lines in 
vitro.35,36 Advanced stages of glioblastoma have been shown to express vitronectin, a 
component of the ECM that is usually absent from normal brain and in early-stage 
gliomas.37 In comparison with fibronectin, laminin and collagen IV, vitronectin is a 
poor adhesive and migratory protein for U251 and SF767 glioblastoma cells.38  
Laminin describes a large group of adhesion glycoproteins that are found in all 
basement membranes and in hyperplastic blood vessels in glioma cells; it is an 
integral part of the glial limitans externa.39 Laminin 5 in particular has recently been 
found to be a promoter of glioma adhesion, invasion and migration, which is 
mediated by integrin α3β2.40 
Besides glycosaminoglycans and glycoproteins, it has been suggested that 
proteoglycans play a key role in brain tumours such as, for instance, tenascin-C, 
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brain-enriched hyaluronic binding (BEHAB, brevican) and versican. Tenascin-C is 
synthesized by glial and neural-crest cells,41 as well as by satellite cells of the 
peripheral nervous system.42 Its expression pattern increases with higher stages of 
tumour malignancy in the area of the surrounding vessel walls.  
The regulation of these important adhesion and migration factors is currently only 
partly understood. It has been shown that transforming growth factor-ß (TGF-ß, a 
member of the cytokine family that comprises homodimeric polypeptides) exerts 
multiple functions that include regulation of cell growth and differentiation, 
immunosuppression, induction of angiogenesis and apoptosis, and promotion of 
ECM production. An effect of TGF-ß2 on invasion has been described in gliomas and 
other model systems, but no conclusive model yet exists. It is only known that these 
effects are very complex, consisting of a step-like process of attachment and 
migration, which involves the components of ECM as well as tumour cells.43  
 
I.3 Versican 
Versican is a proteoglycan of the lectin family. It was initially identified in the culture 
medium of human IMR-90 lung fibroblasts.44 In 1996, versican was identified in 
human brain and brain tumours.45 Versican is encoded by a single gene and is 
located on chromosome 5a 12-14 on the human genome and is called the VACAN-
gene. The gene is divided into 15 exons and has a molecular mass of 500 kDa. 
Versican exists of an N-terminal G1-domain, a glycosaminoglycan-domain (GAG-
domain) and a C-terminal G3-domain. Four isoforms of versican – V0, V1, V2, V3 – 
are generated by means of alternate splicing in the exons of the GAG-domain (Figure 
1).  
V0 contains a GAG-α exon and a GAG-β exon. V1 contains the GAG-β exon. V2 
contains the GAG-α exon and represents the CS-proteoglycan in the brain. V3 
contains only both globular domains.46 Consequently, this isoform exists as a 
glycoprotein and not as a proteoglycan. 
All versican isoforms contain globular domains at the amino terminus (G1) and 
carboxyl terminus (G3).47 The G1-domain is composed of an immunoglobulin-like 
motif, followed by two proteoglycan tandem repeats that bind hyaluronic acid. A linker 
protein mediates the association of versican with hyaluronic acid. Both hyaluronic 
acid and the isolated linker protein have the ability to bind to versican’s G1-domain.48 
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The G3-domain contains two epidermal growth factor-like repeats, a carbohydrate 
recognition domain (a lectine-like repeat) and complement binding protein-like 
subdomains with structural similarity to the selectin family.49 The difference in sizes of 
the chondroitin sulphate attachment regions in between the isoforms suggests that 
the actual number and size of attached chondroitin sulphate chains varies, indicating 
that the possibility of heterogeneity in number, length and molecular structure of 
chondroitin sulphate GAG may lead to different structural and functional diversity 
outcomes. 
 
 
Figure 1: Structure of versican isoforms V0, V1, V2 and V3.50 
 
Versican is able to regulate many cellular processes, including adhesion, 
proliferation, apoptosis, migration and invasion via the highly negatively-charged 
chondroitin/dermatan sulphate side chains and by means of interaction between the 
G1- and G3-domains with other proteins.51,52 The wide range of molecules that have 
the ability to interact with versican via its G1- and G3-domain and chondroitin 
sulphate side chains have recently been reviewed.53 In addition to hyaluronic acid, 
versican binds to ECM components, including tenascin-R, type I collagen, fibulin-1 
and fibulin-2, fibrillin-1 and fibronectin.54 Versican also binds to cell surface molecules 
P- and L-selectin, chemokines, CD44, integrin β1 and epidermal growth factor 
!
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receptor.55 Studies have also shown that versican can bind to specific chemokines 
through its chondroitin sulphate chains and down-regulate chemokine function.56 
 
I.3.1 The role of versican isoforms in normal tissue and in cancer 
There is little information that attributes distinct functions to the individual versican 
isoforms in normal tissue and in cancer.57 Versican isoforms V0 and V1 are mainly 
expressed in the later stages of embryonic evolution. V0 isoform is particularly 
prevalent during early embryonic development, but less well represented in adult 
tissues. Data is now emerging that the V1 isoform may have different functions in 
cells than in isoform V2. Versican isoform V1 has been shown to enhance cell 
proliferation and to protect NIH-3T3 fibroblasts from apoptosis.58 In contrast, isoform 
V2 exhibits opposing biological activities by inhibiting cell proliferation, although it 
lacks any association with apoptotic resistance.59 It has been shown that versican 
isoforms V1 and V2 may also have distinct functions in normal brain tissue.60 In the 
work of Wu et al, V1 has been shown to promote neuronal differentiation of neural 
stem cells and neurite outgrowth of primary hippocampal neurons.61 However, their 
experiments were not able to prove these effects for V2. Further studies have 
proposed an inhibitory effect of versican V2 on axon growth.62 
It has been proven that the expression of versican is elevated in many cancer cells. 
Elevated levels of versican are reported in melanomas, osteosarcomas, lymphomas, 
breast, prostate, colon, lung, pancreas, endometrial and ovarian cancers and in brain 
tumours.63,64 Even non-solid cancers, such as human acute monocytic leukemia 
cells, express V0 and V1.65 Versican appears to be most commonly secreted by the 
peritumoural stromal cells in adenocarcinomas, although human pancreatic cancer 
cells are shown to secrete versican. The expression of versican has also been 
described in endometrial cancer cells and ovarian cancer tissue.66 In ovarian cancer, 
high stromal versican levels correlate with serous cancers and are associated with 
reduced overall survival, whilst high versican levels in epithelial cancer cells are 
correlated with clear cell histology (early FIGO stage) and increased recurrence-free 
survival. Elevated levels of versican in early-stage prostate cancer also predict 
tumour progression.67  Elevated versican levels are associated with cancer relapse 
and poor patient outcome in breast, prostate and many other cancer types.  
                                                                                                                           
   
 17 
V0 and V1 are the predominant isoforms present in gliomas.68 There are no studies 
to date that have investigated whether V0 and V1 versican have different functions in 
astrocytic brain tumours. The smallest splice variant, V3, which consists only of the 
amino- and carboxy-terminal G1- and G3-domains and thus a small glycoprotein 
lacking chondroitin sulphate chains, might be expected to have properties 
considerably different from the other isoforms. However, there have been no studies 
that have directly compared the biological activity of V3 with other versican isoforms. 
The isoform V3 is expressed in primary endothelial cell cultures following activation 
by pro-inflammatory cytokines or growth factors. The role of V3 in activated 
endothelium is not known. The over-expression of V3 in arterial smooth muscle cells 
results in their increased adhesion to the culture flasks but reduced proliferation and 
slower migration in scratch wound assays.69 The over-expression of the isoform V3 in 
melanoma cancer cells, which markedly reduces cell growth in vitro and in vivo, 
actually promotes metastasis to the lung. These findings suggest that isoform V3 
may have a dual role as an inhibitor of tumour growth and as a stimulator of 
metastasis.70,71 Versican is a large chondroitin sulphate proteoglycan produced by 
several tumour cell types, including high-grade glioma. The increased expression of 
certain versican isoforms in the ECM plays a role in tumour cell growth, adhesion and 
migration.72 Versican is localized in either the peritumoural stromal tissue of many 
cancers, being secreted into the ECM by host tissue fibroblasts, or is expressed by 
cancer cells themselves. Studies have revealed that multiple mechanisms are 
responsible for differentially regulating the level, localization and biological function of 
versican in cancer.73 Modulation and remodelling of the ECM mediated by proteases 
and interaction with ECM components like versican may be one mechanism by which 
tumour cells control their microenvironment to facilitate metastasis.74 
Transforming growth factor-ß2 is an important modulator of glioma invasion, partially 
by remodelling the ECM.75 However, it is unknown whether it interacts with versican 
during malignant progression of glioma cells. As previously shown in our lab, the 
expression of versican V0 and V1 is up-regulated by TGF-ß2 detected by quantitative 
polymerase chain reaction and immunoprecipitation, whereas the expression of V2 is 
not induced.76 Using time-lapse scratch and spheroid migration assays, it has been 
observed that the glioma migration rate is significantly increased by exogenous TGF-
ß2 and inhibited by TGF-ß2-specific antisense oligonucleotides.77 Interestingly, an 
antibody specific to the DPEAAE region of the glycosaminoglycan-b domain of 
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versican is able to reverse the effect of TGF-ß2 on glioma migration in a dose-
dependent manner. It has therefore been hypothesized that TGF-ß2 modulates the 
expression of versican.78  
 
I.4 Question and hypothesis 
Regarding reported knowledge about the influence of versican in context with cancer 
cell mirgration and proliferation and the results of previous works in our lab reported 
above, I investigate which role the different isoforms of versican might play in glioma 
cell motility, proliferation and invasion in glioma cell lines. I hypothesize that a 
targeted down-regulation of specific versican isoforms in glioma cells will 
substantially reverse functional effects such as the propagation of invasion.  
 
I.4.1 Methodological approach 
RNA interference (RNAi) is a regulatory mechanism of cells that physiologically 
allows them to control protein expression and to destroy external RNA material of 
viruses. Today, RNA interference is widely used in molecular research to induce 
post-transcriptional regulation of protein expression. Small interfering RNAs (siRNAs) 
are useful when investigating the function of special proteins on apoptosis, cancer, 
gene regulation and many other processes. Small interfering RNAs are 21-26 
nucleotide long RNAs that are cut out of long double-stranded RNAs using an 
enzyme called RNase III Dicer. Artificially created single-stranded RNAs are used as 
RNA interference in molecular research.79  
These small RNAs reach the inside of the cell via transfection, which can be 
performed in different ways. Electroporation and transfection with lipoporus are 
probable ways. Cell walls are permeabilized and the transfectant (siRNA) enters the 
cell through pores in the cell wall.80 Once inside the cell, siRNAs build a protein 
complex with RISC (RNA-induced silencing complex). RISC binds to complementary 
RNA. This complex functions as an RNA helicase and nuclease. RNA is 
consecutively separated and wrested, so intracellular nucleases begin to degrade the 
RNAs and the gene of interest is no longer translated. The resulting gene knock-
down is used to find out about the function of respective genes (Figure 2).  
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A greater understanding of the mechanisms regulating versican expression and the 
activity of its isoforms will assist in the development of specific inhibitors of versican-
mediated cancer cell metastasis. Significant results could lead to the development of 
therapeutic methods to down-regulate versican expression, decrease its catabolism 
or to inhibit its function. 
 
 
 
 
 
Figure 2: Enzymatic mechanism induced by endogenous and exogenous siRNA in the cell.81 
 
Gene silencing via siRNA transfection is a transient effect that lasts a few days, 
whereas transfection with short hairpin RNA (shRNA) enables a stable and inducible 
RNAi system. Short hairpin RNA is a DNA molecule that can be cloned into 
expression vectors. Vectors that express small interfering RNAs within mammalian 
cells typically use an RNA polymerase III promoter to drive expression of a shRNA 
!
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that mimics the structure of a small interfering RNA.82 The insert that encodes this 
hairpin structure is designed to have two inverted repeats separated by a short 
spacer sequence. Once inside the cell, the vector constitutively expresses the hairpin 
RNA, which induces silencing of the target gene (Figure 3).83 
 
 
 
 
Figure 3: Enzymatic mechanisms in a cell transfected with a short hairpin vector.75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!
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Material and methods 
I.5 Materials 
Chemical Company 
Ampicillin Sigma 
Sodium pyrophosphate Sigma 
10xTris/Glycine/SDS  Bio-Rad 
Methanol Uni.-Lager 
2’-Desoxyadenosine-5’-triphosphate Sodium Salt (dATP)  Sigma 
2’-Desoxycytidine-5’-triphosphate Sodium Salt (dCTP)  Sigma 
2’-Desoxyguanosine-5’-triphosphate Sodium Salt (dGTP)  Sigma 
2’-Desoxythymidine-5’-triphosphate Sodium Salt (dTTP)  Sigma 
Tween 20 Sigma 
30% Acrylamide/Bis Sol. 37% 5:1 BioRad 
Bovine Serum Albumin PAA 
LE Agarose Biozym 
70% Propanol a 1l Braun 
99% Alcohol 10l Uni 
Aceton Uni. Chem. 
Acrodisc Syring Filter 0.2um PALL/VWR 
Acrylamide/Bisacrylamide (19:1)  Roth 
Adenosine  Sigma 
Adenosine-5’-diphosphate Sodium Salt (ADP) Roth 
Adenosine-5’-triphosphate Sodium Salt (ATP)  Roth 
AllStars Neg. Control siRNA Qiagen 
Ammonium Persulphate ((NH4)2SO4)  Roth 
AMV Reverse Transcriptase Promega 
BCA Protein Standard KMF 
Betaine  Sigma 
Bromphenol Blue  Roth 
BZO Seal-Film Biozym 
Calcium Chloride (CaCl2)  Sigma 
Calf Phosphatase Calbiochem 
Chondroitinase ABC Sigma 
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Complete Cocktail Tablets Roche 
Dithiothreitole (DTT)  Sigma 
DMEM High Glucose PAA 
DMEM Low Glucose, à 500ml PAA 
DMSO Sigma- Aldrich 
EDTA-Trypsin PAA 
Ethanol  Roth 
Ethidium Bromide  Roth 
Formamide  Sigma 
Glucose  Sigma 
Glucosamin-HCl  Fluka 
Glycerin  Sigma 
Glycerol-2-Phosphate Sigma 
HCL Uni. Chem. 
Hemacolor 2, blue Merck 
Hemacolor 2, red Merck 
HiPerfect Transfection Reagent 1ml Qiagen 
HP Flexible siRNA Design, V3 Qiagen 
Hyperfilm ECL 25 sheets 18x24cm Amersham  
Immobilon Western HRP Substrate 250ml Millipore 
Laemmli Sample Buffer 30ml BioRad 
L-Glutamine  PAA 
Lipofectamine 2000 Invirtogen 
Lipofectamine Transfection Reagent Invitrogen 
Magnesium Chloride (MgCl2)  Roth 
MAPK-1 AK Taq 100 Qiagen 
MAPK1 Ko. siRNA Qiagen 
Matrigel 20ml Dianova 
MEM Vitamins PAA 
Methanol Roth 
Methylen Blue Merck 
Millipore-Q-Kit-Pack Millipore 
N,N,N’,N’-Tetramethylethylendiamine (TEMED)  Roth 
NaCl  Roth 
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NaHCO3  Merck 
NaOH  Roth 
Sodium Acetate  Roth 
Sodium Citrate Sigma 
Sodium  Roth 
Neg. Control siRNA Qiagen 
NEM Non. Essential Amino Acids a 100ml PAA 
PBS-MgCl/-CaCl  PAA 
Phosphatse Inhibitor Cocktail Sigma 
Plus Reagent (3mg/ml) 0.85ml Invitrogen 
Polyethylen Glycol  Roth 
Potassium Chloride  Roth 
Precision Plus Protein Standards 500ul Biorad 
Reblot-Plus Strong Solution Chemicon 
Sodium dodecyl sulphate Lauryl Sulfat 
Substrate Reagent R&D 
Sucofin Skimmed Milk Real 
Supersignal West Piro ECL Subst. 100ml Pierce 
Tris(Hydroxylmethyl)-Aminoethan (Tris) Sigma 
Triton-X 100 Sigma 
Trizma Hydrochloride Sigma-Aldrich 
Trypanblue 0.5% Biochrom 
Trypsin-EDTA, a 100ml PAA 
Uridine-5’-triphosphate (UTP) 
 
 
 
 Buffers 
 Easy lysis buffer 10mM TrisHCl pH 8.0 
 
1mM EDTA 
 
15% Saccharose 
 
0.2mg/ml RNAseA 
 
2mg/ml Lysozym 
 
0.1mg/ml BSA 
TBS Buffer  8g NaCl 
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0.2g KCl 
 
3g Tris- Base pH 7.4 
 
ad 1000 ml H2O 
SDS-Running Buffer 288.4g Glycin 
 
10g SDS 
 
60.6g Tris 
 
ad 100ml H2O 
DEPEC water 1ml Diethylpyrocarbonate 
 
ad 1000ml H2O 
PBS  8g NaCl 
 
1.15g Na2HPO4 
 
0.2g KCl 
 
0.2g KH2PO4 
 
ad 1000ml H2O 
Ponceau red dye solution 0.5g Ponceau 
 
1% Ice acid 
 
ad 500ml H2O 
RIPA buffer 50mM Tris/HCl pH 7.5 
 
150mM NaCl 
 
0.5% Na-desoxycholate  
 
Protease inhibitor 
 
0.1% SDS 
 
1% NP-40 
TBE buffer 45mM Tris-Borat pH 8.3 
 
1mM EDTA 
TBST buffer 10mM Tris-HCl pH 8.0 
 
150mM NaCl 
 
0.05% Tween 
Transfer buffer 39mM glycerin 
 
48mM Tris  
 
0.03% SDS 
 
20% methanol 
APS 25% 25g NH4-Persulphate 
 
ad 100 ml H2O 
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Blot buffer 25nM Tris pH 8.5 
 
10% Ethanol 
 
190nM Glycine 
Freezing medium 90% FCS 
 
10% DMSO 
Stripping solution 1ml Reblot Strong Solution 
 
19ml H2O 
Lämmli buffer 1.25ml 1M Tris pH 6.8 
 
0.7ml 87% Glycerine 
 
2ml 10% SDS 
 
2.5mg Bromphenoleblue 
 
ad 10ml H2O 
Ethidiumbromide stock solution 1g Ethidiumbromide 
 
ad 100 ml H2O 
  
Consumables 
 Biofreeze tubes PP 2ml Corning 
Cover slips 24x60cm Roth 
Nitrocellulose membrane Schleicher und Schuell 
Plastic requirements Corning Costar 
PVDF membrane, 13mm, 8µm Schleicher und Schuell 
Super frost glass slides Roth 
Whatman paper 3MM Whatman VWR 
  
Vector system 
 pENTER-THT (KAN)  Invitrogen 
 
 
 Cell lines 
 
A172 
Glioblastoma multiforme  
(WHO grade IV) 
U87 Anaplastic astrocytoma 
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(WHO grade III) 
HTZ349 
Glioblastoma multiforme  
(WHO grade IV) 
HTZ417 
Glioblastoma multiforme  
(WHO grade IV) 
DH5α E. coli stem  
 
 
Cell culture medium 
 Full medium 500ml Dulbecco’s MEM 
 
5ml non-essential amino  
acids 
 
5ml vitamins 
 
25ml FCS 
LB-O medium 10g Tryptone 
 
5g yeast extract 
 
10g NaCl 
SOB medium 20g Tryptone 
 
5g yeast extract 
 
0.6g NaCl 
 
0.2g KCl 
 
2g MgCl2 
 
2.5g MgSO4 
Transfection medium Optimem 
 
 
Enzymes 
 HinD III Promega 
Alkaline phosphatase  Böhringer Mannheim 
BGL II Roche 
DNaseI Böhringer Mannheim 
Restriction endonuclease Fermentas 
Taq DNA Polymerase  Roche 
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RNase/protease inhibitors 
RNasin (RNase inhibitor)  Promega 
Trypsin inhibitor  Roche 
   
Size/lengthe standards 
 
 (2x250µl) Page Ruler Plus Pertained Protein Ladder Fermentas 
(2x250µl) Spectra Multicolor Broad Range Protein Ladder Fermentas 
1kb RNA-ladder (RNA-Standard)  Gibco BRL 
Gene Ruler DNA-ladder Mix (DNA-Standard)  Fermentas 
SDS-PAGE Broad Range (Protein-Standard) Bio-Rad 
  
  Antibodies  
Anti Versican V0/V1 Neo Antiboy, Rabbit Polyklonal IgG Biosource 
Ap 124P Gt x Ms IgG Chemicon  
Goat F(ab’)2 Anti Rabbit Ig’s, HRP Conjugate; Biosource 
LDH a 
 Rabbit Anti-Actin  Sigma 
Rabbit Anti-Goat IgG, HRP Conjugat Millipore 
Rabbit Anti-Versican V0/V1 Neo Polyclonal AB BioReagent 
ß-Actin mouse polyklonal 0.2ml Sigma 
TGFß2 rec. human 5µg Tebu.Bio 
 
 
 Kits 
 Quanti Tec SYBER Green PCR Kit Qiagen 
Reverse Transcription Kit Promega 
RNAeasy Kit Qiagen 
RNase-free DNase Kit Qiagen 
siRNA Starter Kit, QuantiTect Assay, SiRNA Design Qiagen 
Taq PCR Master Mix Kit Qiagen 
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Hardware 
 Bx51 Olympus 
Centrifuge 3K 30 Sigma 
EC 4000P  Apparatus Corporation 
ELISA-Reader Biotrend 
Incubator Heraeus 
Megafuge 1.0 R Hareaus instruments 
Microscope Leica 
Real-time quantitative PCR systems Stratagene 
Thermal Cycler PTC 200 Peltier 
Ultrospect 3000 Spectrophotometer Pharmacia Biotech 
 
 
 Software 
 Microsoft Excel 2003 
 Adobe Illustrator 11.0 
 ImageJ 
 Adobe Photoshop 8.0 
 Microsoft Word 2003 
MxPro Software 
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I.6 Methods 
I.6.1 Cell culture 
I.6.1.1  Glioma cell lines 
Different types of glioma cell lines and primary cultures were used for the in vitro 
experiments. Human high-grade glioma cell lines U87MG and A172 were obtained 
from the American Type Culture Collection (Manassas, VA, USA). The glioma cell 
lines HTZ349 and HZT417 are primary tumour cell cultures derived from surgical 
specimens of human high-grade gliomas (WHO grade IV) as described by Bogdahn 
et al (1989).84 All tumour cells were maintained as standard monolayer cultures in 
tumour growth medium at 37°C, 5% CO2, 95% humidity in a standard tissue culture 
incubator (Heraeus). 
 
I.6.1.2  Cell culture medium 
The growth medium comprised Dulbecco’s modified Eagle medium (DMEM), low 
glucose 1g/l (PAA) supplemented with 5% foetal calf serum (FCS), 1% non-essential 
amino acids (PAA) and 1% MEM-vitamins (PAA). Glioma cells were seeded at an 
equal density in cell culture flasks containing growth medium. The culture medium 
was replaced 24 hours after thawing the cells and was then replaced twice a week. 
Cells were cultivated with 15–20ml of culture medium in a 175cm2 flask or with 10–
15ml of culture medium in a 75cm2 flask. 
 
I.6.1.3  E. coli cell culture  
The bacterial colony was gathered using 250ml SOB medium under permanent 
shaking at 37°C until its concentration reached an optical density of 0.6 at OD600. 
Bacteria were diluted with 60% LB and 40% glycerin at a dilution of 1:1. The cell 
suspension was aliquotated in cryo-tubes and stored at -80°C. Plasmid amplification 
was performed in an E. coli strain called DH5α. Non-transformed bacteria were 
cultivated at 37°C in LBO-medium. Ampicillin-resistant clones were cultivated in an 
LB-Ampicillin medium.  
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I.6.1.4  Cell passage   
Prior to each experiment or passage of a cell line, cells were detached by 
trypsination. Cells were flushed with 5–7ml PBS (PAA) for 30 seconds. Then the cell 
monolayer was coated with 5ml of trypsin (PAA) in a 175cm2 flask. After 5–10 
minutes incubation at 37°C in the tissue culture incubator, trypsin reaction was 
stopped by adding 5ml of the culture medium to the flask. The bottom of the culture 
flask was flushed three times using the trypsin/culture medium suspension. The 
suspension was transferred to a reaction flask (15ml) and centrifuged for 5 minutes at 
1,500 RPM at RT (Megafuge, Hareaus instruments). After discharging the 
supernatant, the cell pellet was dissolved in 1ml of culture medium and the cell 
concentration was defined. 
 
I.6.1.5  Cryoconservation 
Cryoconservation is used to store cells for a long period at -130°C. At these low 
temperatures, any biological activity, including the biochemical reactions that would 
lead to cell death, are effectively stopped.  
Cells were kept in a special medium consisting of DMSO, FCS and culture medium 
(dilution 10:40:50) to avoid damage to cells during freezing or warming up. The cells 
were put in a Biofreeze tube and slowly frozen to -80°C and then stored in liquid 
nitrogen.  
 
I.6.2 Cell count 
For cell culture and many other applications the exact cell concentration of a sample 
needs to be determined. Determining cellular proliferation, viability and activation are 
key to a wide variety of cell biological approaches. The need for sensitive, 
quantitative, reliable and automated methods has led to the development of standard 
assays.  
 
I.6.2.1  Direct cell count 
A Neubauer counting chamber device was used to determine the number of cells 
(Figure 4).  
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Figure 4: Counting chamber.85  
 
The cell suspension was introduced into one of the V-shaped wells using a pipette. 
The area under the cover glass was filled by means of capillary action. The loaded 
counting chamber was then placed under a microscope and the counting grid 
brought into focus at low power (Figure 5). Cells were counted systematically in 
selected squares. 
 
	  
 
Figure 5: Counting grid.86 Small square measures 1/400mm2, 16 small squares measure 
1/25mm2 
 
 
 
!
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The total cell count was calculated by multiplying the dilution factor (DF) by cell count 
(CC), volume of cell suspension (CS) and volume of filled chamber (Ch). 
                                           
                                           DF x CC x (CS) ml x (Ch) 10000 
 
I.6.2.2  XTT assay 
Cells grown in a 96-well tissue culture plate were incubated with 20µl of the yellow 
XTT solution (final concentration 0.3mg/ml) for 4 hours. After this incubation period, 
orange formazan solution had formed and was spectrophotometrically quantified 
using an ELISA plate reader. This assay is based on the cleavage of the yellow 
tetrazolium salt XTT. Metabolically active cells convert the yellow tetrazolium salt into 
an orange formazan dye. This conversion only occurs in vital cells. The formazan dye 
is directly quantified using a scanning multi-well enzyme-linked immunosorbent assay 
(ELISA). This ensures a high degree of precision and enables computer processing 
of the data, which allows the rapid and convenient handling of a high number of 
samples. 
An increase in the number of living cells resulted in an increase in the overall activity 
of mitochondrial dehydrogenases in the samples. This increase directly correlated to 
the amount of orange formazan formed, which was monitored as the absorbance.87 
 
I.7 Preparing RNA 
I.7.1 RNA isolation 
General requirements when handling RNA are that the endogenous RNases stay 
inactivates and the samples, solutions and materials are not contaminated with 
exogenous RNase. All solutions were prepared with 0.1% DEPEC water.88  
Total RNA was extracted from tumour cells using the RNeasy Mini Kit (Qiagen, 
Hilden, Germany) RNA purification system following the manufacturer’s instructions. 
All steps were accomplished on ice. 
First the RTL-buffer was set up, consisting of 3ml RTL-lysis buffer (Quiagen) and 
30ml ß-mercaptoethanol (Sigma). The frozen cell pellets were suspended in 350µl 
RTL-buffer and vortexed for 1 minute after adding 350µl of ethanol (70%). The 700µl 
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of cell suspension was transferred to a collection column and centrifuged for 30 
seconds at 10,000 RPM. Ethanol and ß-mercaptoethanol were discharged from the 
lower compartment of the collective column. 700µl RW1-buffer was added to the 
column and centrifuged for 30 seconds at 10,000 RPM. The lower compartment of 
the collective column was discharged and the column placed in a 2ml tube. 500µl 
RPE-buffer was added to the column and centrifuged first for 15 seconds at 10,000 
RPM. In a second step, another 500µl of RPE-buffer was added and the column was 
centrifuged at 10,000 RPM for 2 minutes. Subsequently, the column was placed in a 
1.5ml tube and incubated with 30µl RNase-free water for 1 minute and placed in the 
centrifuge for 1 minute at 10,000 RPM. The 30µl of RNase-free water, which was 
now in the lower compartment, was again placed in the column and the centrifugation 
step was repeated. The RNA concentration in the samples was measured and the 
probes stored at -80°C. 
The RNA concentration and purity was determined by measuring the optical density 
at wavelengths of 260nm and 280nm using the Ultraspect 3000 spectrophotometer 
(Pharmacia Biotech). The blank value for calibration consisted of 100µl water. 10µl of 
RNA sample was diluted with 90µl water (1:10). The concentration of RNA in the 
samples was calculated in µl/ml, taking account of the dilution factor. 
 
I.7.2 Reverse transcriptase polymerase chain reaction (RT-PCR) 
First, strand cDNA was generated from 0.5–1µg of total RNA. Gene-specific cDNAs 
were synthesized using a reverse transcription kit (Promega). Appropriate forward 
and reverse primers were used in the reverse transcriptase polymerase chain 
reaction (RT–PCR) for cDNA amplification. A Master mix was prepared for reverse 
transcriptase-PCR (Table 1). 
 
MgCl2 4µl 
10x buffer 2µl 
dNTPs 2µl 
Oligo dt-primer 1µl 
AMV RTase 0.6µl 
RNasin 0.5µl 
Aqua dest. 0.9µl 
 
Table 1: Mastermix for RT-PCR. 
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Samples of 1µg RNA were filled up to a volume of 9µl with DEPEC water and mixed 
with 11µl of Master mix. The RNA was transcribed during 15 minutes of incubation at 
42°C. Adding 80µl H2O, cDNA was dissolved and stored at -20C°. The RT-PCR 
programme in the light cycler was run at 42°C for 15 minutes, followed by 95°C for 5 
minutes and 4°C for 5 minutes. 
 
I.8 DNA synthesis and analysis 
I.8.1 Polymerase chain reaction 
The polymerase chain reaction (PCR) is a technique used to amplify copies of a 
piece of DNA that generates millions of copies of a specific DNA sequence. A PCR 
involves a series of different steps, including denaturation of a DNA double strand, 
annealing of specific primers to the DNA template and synthesis of the DNA with a 
polymerase. The method relies on thermal cycling, comprising cycles of repeated 
heating and cooling that melt DNA double-strands and induce enzymatic replication 
of the DNA. Primers are short DNA fragments with complementary sequences to the 
target region. They bind to the 5’end of the DNA template at a certain annealing 
temperature. After that, a DNA-polymerase is activated and enables amplification of 
the complementary DNA strand after adding dNTPs. The generated DNA is used as 
a template for the next replication.  
Prior to starting the PCR, a reaction mix was prepared containing the following 
components (Table 2). 
 
cDNA 1µl 
Primer forward 0.5µl 
Primer reverse 0.5µl 
Taq-polymerase 25µl 
Aqua dest. 23µl 
 
Table 2: Reaction mix in PCR. 
 
When preparing the reaction mix all the components were stored on ice. The 
samples were placed in a master cycler (Eppendorf AG) using an individual 
programme for each primer pair. Initially, the DNA polymerase was activated at 95°C 
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for 5 minutes, followed by a DNA amplification step for 30 cycles (95°C for 45 s, 57–
60°C for 1 min, 72°C for 45 s), which was extended by 5 minutes at 72°C.  
 
I.8.1.1  Primer design 
Primer design is done with help of a NCBI primer-designing tool.89 The following 
criteria are taken into account: after defining the accession of the mRNA template, 
the position ranges for forward and reverse primers are entered so that primers are 
located on specific sites of the target genes. PCR product size and melting 
temperatures (Tm) are determined. Further primers used to transcribe RNA to cDNA 
need to span an exon–exon junction in mRNA. 
Primer length was chosen in between 17–28 bases. The tool takes account of the 
base composition, which should consist of 50–60% G+C and includes a 3’-end of a G 
or C, or CG or GC. Tm was calculated between 55–80oC. Further it was checked that 
the 3’-ends of primers were not complementary. Runs of three or more Cs or Gs at 
the 3’-ends of primers were avoided, as were G or C-rich sequences.90 Any 
additional homology was excluded by blasting primer sequences through the NCBI 
gene pool database.91 Table 3 shows all primer sequences used. 
 
V0 Sense 5’GAC AGG TCG AAT GAG TGA TTT GAG 3’  
 Antisense 5’GCC ATT AGA TCA TGC ACT GGA TCT G 3’ 
      
V1 Sense 5’GAT GCC TAC TGC TTT AAA CGT CG3’  
 Antisense 5’GGT TGT CAC ATC AGT AGC ATT TGC3’  
      
V2 Sense 5’-TCACGACTTCAAGTCCTCCTGC-3’  
 Antisense 5’- GGTGCCTCCGTTAAGGCACG -3’   
      
V3 Sense 5’- GTGTGGAGGTGGTCTACTTGG-3’  
 Antisense 5’- GGTGCCTCCGTTAAGGCACG -3’   
 
Table 3: Primers targeting versican isoforms V0, V1, V2 and V3 and their sequences. 
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I.8.2  Plasmid amplification in DH5α 
I.8.2.1  Generation of competent DHα bacteria 
Free DNA was transformed in competent cells, called E.coli strain DH5α. DH5α was 
cultivated in an LB-O medium. Ampicillin-resistant bacteria were cultivated in an LB-
Ampicillin medium. DH5α E.coli bacteria were scratched out onto an LB-agar plate. 
The bacterial colony was gathered using 250ml SOB at a concentration of OD600= 
0.6. Bacteria were placed on ice for 10 minutes, then centrifuged at 2,500 RPM for 
10 minutes at 4°C and suspended in 20ml transformation buffer. After incubation for 
another 10 minutes, competent bacteria were aliquotated and stored at -80°C. 
 
I.8.2.2  Heat-shock transformation of chemo-competent DH5α 
10–100ng of plasmid were added to 50µl of competent DH5α and incubated for 15–
30 minutes on ice. Heat shock was performed for 90 seconds at 42°C. Afterwards, 
bacteria were cooled down on ice and cultivated with 400µl of SOB-medium in a 
shaking incubator at 37°C. Finally, the bacteria were placed on a resistance medium 
and stored at 37°C. 
 
I.8.2.3  Mini Prep  
Mini Prep is a method that is used to purify plasmid-DNA. Clones were collected from 
the plate using the tip of a pipette and were given into selection medium containing 
3ml LB medium + Ampicillin 100µg/ml for 12–24 hours at 37°C in a shaking 
incubator. 1.5ml of bacteria suspension was centrifuged at 16,000 RPM for 20 
seconds. The cell pellet was suspended in 50µl of easy lysis buffer and incubated for 
5 minutes at RT. Then cells were cooked for 2 minutes and cooled down on ice. 
During this procedure the bacteria cell walls rupture, allowing DNA to be isolated. 
After centrifuging at 16,000 RPM for 10 minutes at 4°C, bacterial DNA and cell debris 
were removed and the plasmid dissolved in the supernatant. 
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I.8.2.4  Maxi Prep 
To gather larger amounts of plasmids, one clone is picked out of the plate using the 
tip of a pipette. This clone arises from transformed DH5α bacteria, which are 
incubated overnight at 37°C.  
The clone was incubated overnight at 37°C in a shaking incubator with 500ml LB-
medium and Ampicillin. The saturated E. coli stem was filled into a GSA tube and 
was then centrifuged at 5,000 RPM for 10 minutes at 4°C. The pellet was then 
suspended in 10ml of buffer 1. After adding 10ml of buffer 2, the reaction mix was 
mixed until the solution appeared to be clear. Next, 10ml of buffer 3 was added and 
incubated for 15 minutes on ice, followed by centrifuging at 10,000 RPM for 10 
minutes at RT. The pellet was then briefly washed with 100µl ethanol and suspended 
in 2ml TE, pH 7.6. Then 8ml of DNA binding solution was added and incubated for 5 
minutes at RT. In the next step the pellet, charged with DNA binding solution, was 
added to a column. This column was attached to a vacuum. The column was washed 
first with 30ml washing solution and then with 5ml 80% EtOH. Then the column was 
dried in a 50ml tube at 3,000 RPM for 10 minutes. After that, the column was 
attached to a vacuum for another 5 minutes. Finally, DNA was eluted from the 
column, after1.5ml TEs (75°C) was added at 3,000 RPM for 10 minutes.  
 
I.8.2.5  DNA purification 
The first step in DNA purification involves phenol extraction. The plasmid is mixed 
with phenol/chloroform/isoamylalcohol at a ratio 1:1, after which it is vortexed for 1 
minute and then centrifuged for 5 minutes at 14,000 RPM. The supernatant is 
transferred into a new Eppendorf tube and is mixed with chloroform/isoamylacohol at 
a ratio 1:1. After brief vortexing and centrifugation for 5 minutes at 14,000 RPM, the 
supernatant is transferred into a new tube ready for DNA precipitation.  
DNA precipitation was done using sodium acetate. 1/10 volume of 3M sodium 
acetate (pH 5.2) and 2.5 volume 100% ethanol were added to phenol-extracted DNA; 
the solution was incubated at -20°C for 20 minutes. A pellet of DNA formed after 20 
minutes of centrifugation at 4°C and 14,000 RPM. The pellet was washed with 70% 
ethanol and dried at RT. The pellet was then dissolved in 20µl TE buffer. To check 
the integrity of purified DNA a gel electrophoresis was performed and the DNA 
content of the samples was measured photometrically. 
                                                                                                                           
   
 38 
I.8.2.6  HIRT-DNA extraction 
The HIRT protocol serves to isolate plasmids from human cells.  
A 6-well plate was harvested, one third of the cells were centrifuged for 5 minutes at 
14,000 RPM, then washed in 100µl PBS and suspended in 100µl HIRT-reagent 
consisting of 400mM NaCl, 10mM EDTA, 10mM Tris 7.5 and 50µg/ml ProteinaseK 
0.2% SDS. The lysate was incubated for 3 hours at 55°C. Adding 30µl 5M NaCl, the 
cell lysate was incubated overnight at 4°C. After centrifugation for 1 hour at 14,000 
RPM at 4°C, phenol/chloroform/isoamylalcohol extraction and DNA precipitation was 
performed as described in the above. The pellet was then suspended in 5µl of TE 
buffer. Subsequently, 2.5µl of the solution was transformed into DH5α via heat-shock 
transformation.  
 
I.8.3  Electrophoresis 
Electrophoresis describes the migration of negatively charged molecules under the 
influence of an electrical field. Migration time in the electrical field varies and is 
dependent on the molecular weight of the samples.  
 
I.8.3.1  Agarose gel electrophoresis  
PCR products were analyzed on 1% agarose gels. 100ml H2O was heated together 
with 1mg agarose (Biozym) for 2–5 minutes in a microwave at 500W. The gel was 
cooled down to 60°C and then filled onto the slide in the electrophoresis chamber. 
The gel was stacked in the electrophoresis chamber. Slots for samples were 
generated using the inserted comb. After the gel had hardened, the comb was 
carefully removed and the chamber was filled up with DEPEC-water to the sea 
marker. Samples were then loaded onto the gel slots, adding 1µl of ethidium bromide 
to 10µl of each sample. 5µl of a 500bp ladder was used as the size marker. Gel 
electrophoresis was performed at 120mA for 30 minutes. PCR products were 
visualized in a Vilbert Lourmat chamber.  
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I.8.4  Gradient PCR 
Gradient PCR offers the opportunity to investigate primer-binding behaviour at 
different annealing temperatures at the same time, in one run. Based on the primer 
sequences, primer pairs show varying binding behaviour at different annealing 
temperatures.92 Optimal conditions for each primer pair are defined in a gradient 
PCR. The gradient cycler (Mastercycler Gradient, Eppendorf) is able to generate up 
to 12 different temperatures in one run.  
The range of temperatures was chosen between 54°C and –65°C (54°C, 54.3°C, 
54.9°C, 55.8°C, 57.1°C, 58.7°C, 60.6°C, 62.2°C, 63.3°C, 64.2°C, 64.8°C, 65°C). As 
the Eppendorf Mastercycler Gradient also provides a gradient function for elongation 
or denaturation temperatures, the duration of the annealing temperature was tested 
for 30 seconds and 1 minute. The concentration of cDNA varied between 0.5 and 
1µg. The volume of primers was examined from 0.5–1µl. All other components of the 
reaction mix are fixed. Samples were analyzed in agarose gel electrophoresis.  
 
I.8.5  Quantitative PCR 
Quantitative mRNA expression levels were analyzed in a real-time PCR system (ABI 
PRISM 7000 Sequence Detection System, CA, USA) using SYBR Green dye I. A 
positive reaction was detected through the accumulation of a fluorescent signal 
measured using MxPro-Mx3005P software. A mitochondrial 18s housekeeping gene 
was used as a reference gene in the cells. It was present in all nucleated cell types, 
since it is indispensable for cell survival. The mRNA synthesis of these genes is 
considered to be stable and secure in various tissues, even under experimental 
treatment.93  
First, two master mixes were prepared, one with the primer pair targeting the gene of 
interest and the other with the primer pair targeting the housekeeping gene (18s). 
Prior to preparing the reaction mix, Syber Green was melted on ice and carefully 
vortexed before use. All components and the master mix were stored on ice during 
preparation. Table 4 shows the composition of Master mix in qPCR. 
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cDNA 1µl 
Primer forward  0.5µl 
Primer reverse 0.5µl 
Syber Green 12.5µl 
Aqua dest. 10.5µl 
 
Table 4: Master mix for quantitative PCR with a final volume of 25µl. 
 
PCR results were interpreted based on the standard curve. The standard curve 
consisted of a dilution series containing five values up to a 1:16 dilution. The stock for 
a standard dilution series contained 1.5µl of each cDNA sample. In the first standard, 
6µl of the cDNA stock and 6µl H2O were mixed; the second standard contained 6µl of 
the first standard and 6µl H2O and so on. The volume of the samples was adjusted 
using aqua dest. to achieve a final volume of 25µl.  
Samples were analyzed in a 96-well plate. Each sample was loaded in duplicate. 
24µl of the Master mix was loaded into each well using a multi-pipette. 2µl of cDNA 
standard series was filled into each well dedicated to standard curve and 2µl of cDNA 
was filled into the respective well of each sample. Standard samples of cDNA were 
amplified in duplicate with the primers of the housekeeping gene and primers of the 
target gene. Samples were loaded in triplicate for each primer pair. Figure 6 shows 
the assignment. 
 
PH
Kg 
Neg
. 
St1 St1 St2 St2 St3 St3 St4 St4 St5 St5 
PTg Neg
. 
St1 St1 St2 St2 St3 St3 St4 St4 St5 St5 
PH
Kg 
S1 S1 S1 S2 S2 S2      
PH
Kg 
S3 S3 S3 S4 S4 S4      
PTg S1 S1 S1 S2 S2 S2      
PTg S3 S3 S3 S4 S4 S4      
 
Figure 6: 96-well plate with samples: PHKG = Primer housekeeping gene, PTg = Primer target 
gene, St1-St5 = standard values of dilution series, S1-S4 = samples 1–4. 
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After loading the Master mix and cDNA onto the 96-well plate, the plate was closed 
using a bonding sheet and centrifuged for 30 seconds at 6,000 RPM. The plate was 
then placed in a real-time cycler (Stratagene) and the data were recorded using the 
MxPro software. Before the run was started, a thermal profile needed to be defined 
(Figure 13). The plate set-up was done and standard dilution samples were defined. 
Agarose gel electrophoresis was used to verify the identity of the amplification 
products and was performed as described in the above.  
 
I.9 Stable and transient transfection 
I.9.1  Design of siRNAs 
The siRNAs were designed in line with general guidelines and according to the work 
and findings of Elbashir SM et al (2001).94 Table 5 shows the siRNA sequences.  
 
 
 Target 5`-GGG AGU UCU UCG AUU CCA ATT-3` 
V1 Sense 5`-r(GGG AGU UCU UCG AUU CCA A )dTdT 
 Antisense 5`-r(UUG GAA UCG AAG AAC UCC C)dTdT 
 
 Target 5´- AGA AAA TAA GAC AGG ACC TGA- 3` 
V2 Sense 5`-r(AAA AUA AGA CAG GAC CUG A)dTdT 
 Antisense 5`-r(UCA GGU CCU GUC UUA UUU U)dCdT 
 
 Target 5`-TAC TGC TTT AAA CGA CCT GAT-3`  
V3 Sense 5´-r(CUG CUU UAA ACG ACC UGA U)dTdT 
 Antisense 5`-r(AUC AGG UCG UUU AAA GCA G)dTdA 
 
Table 5: Sense-, antisense-siRNA sequences and target sequences of versican isoforms V1, V2 
and V3. 
 
I.9.2  Calculating the siRNA amount 
Initially, the siRNA was delivered lyophilized and was suspended in 250µl of the 
suspension buffer provided prior to the transfection procedure. The suspension buffer 
was added to a 1ml tube containing 5nmol of lyophilized siRNA to obtain a 20µM 
solution. Tubes were heated to 90°C for 1 minute and then incubated at 37°C for 60 
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minutes. The incubation steps were only needed the first time the siRNA was used. 
The siRNA solution was stored at -20°C.   
 
I.9.3  Optimizing siRNA transfection 
Table 6 summarizes the manufacturer’s recommendations regarding the amount of 
siRNA, volumes of medium and concentrations of siRNAs in different experimental 
settings (Table 6).  
 
Culture 
format 
Vol. of 
medium on 
cells (/ml) 
SiRNA 
amount 
(/ng) 
Final 
volume of 
diluted 
siRNA (/µl) 
Final siRNA  
concentration  
(/nM) 
       
48-well 
plate 250 19 50                 5       
24-well 
plate 500 37.5 100                 5   
12-well 
plate 1100 75 100                 5   
6-well  
plate 2300 150 100                 5   
 
       
Table 6: Instructions regarding siRNA transfection with calculated amounts of siRNA and 
medium in different culture formats 
I.9.4  Sh-RNA 
I.9.4.1  Insert design  
The shRNA-insert consisted of a 19bp-long stem and a loop 9bp in length. The 
elements were arranged in a sens- loop-antisense direction. The insert was initiated 
with the sense-sequence at the 5’´end, which is homologous to the sequence of 
target mRNA, followed by the loop sequence: UUCAAGAGA. The loop sequence 
was followed by a reverse complementary sequence of the sense strand. A string of 
5 thymidines was added to the antisense strand as the termination site for the 
polymerase III.  
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I.9.4.2  Transforming specific siRNA into vector 
The sense sequence in our siRNA template insert corresponded to the siV1-target 
sequence (Table 5). The shRNA insert was formed by means of the kinasation of the 
oligonucleotides, which adhere to the reaction mix. All ingredients were stored on ice 
when preparing the reaction mix (Table 7). Oligonucleotides were synthesized and 
annealed containing 1µg of a sense and an antisense strand of the siRNA at 37°C for 
1 hour.  
 
Oligo B (10 µM) 1µl 
ATP (10mM) 1µl 
10x PNK Buffer 1µl 
Aqua dest. 5µl 
T4 Polynucleotide kinase 1µl 
 
Table 7: Reaction mix for kinasation of oligonucleotides  
 
The annealing step was performed at 95°C for 2 minutes. After brief centrifugation, 
the reaction mix was incubated for 1 hour at 37°C and then diluted at 1:10 with aqua 
dest. For ligation of the oligonucleotides and the vector, a reaction mix consisting of 
the following adjuvants was incubated for 10 minutes at RT (Table 8). 
 
Vector (100ng) 1µl 
Kinase mix (1:100 dilution) 1µl 
Aqua dest. 1µl 
2x Buffer 5µl 
5x Buffer 2µl 
T4 DNA Ligase 0.5µl 
 
Table 8: Reaction mix for kinasation of oligonucleotides and vector 
 
The vector pENTER-THT (KAN) was used. The vector was transformed into 
competent cells of an E.coli strain. 20µg of the vector was cut using the restriction 
enzymes Bgl II/HinDIII within an incubation time of 1–2 hours at 37°C. 
Transformation was done in DH5 α as described in the above. On PCR level the 
identification of positive clones was done using specific primers. Table 9 shows the 
Master mix used for PCR. 
                                                                                                                           
   
 44 
ON x 20 pmol/µl 1µl 
ON y 10 pmol/µ 2µl 
10x Taq Buffer 5µl 
dNTPs (2 mM) 5µl 
Aqua dest. 36µl 
Taq DNA Pol 1µl 
 
Table 9: PCR mix 
 
I.9.5  Transfection of adherent cells 
I.9.5.1  SiRNA transfection of adherent cells 
Cells were transfected according to the manufacturer’s instructions (Invitrogen). For 
transfection of adherent cells, cells were harvested and counted as described in the 
above. Experiments were run with 200,000 cells per well in a 6-well plate. When 
preparing the transfection mixture, Lipofectamine 2000 (Invitrogen) and the 
calculated amount of siRNA (Table 6) were diluted in 250µl Optimem medium 
(Invitrogen) and incubated separately for 5 minutes at RT while being stored on ice. 
Afterwards, the two collection tubes were mixed and incubated for another 20 
minutes in a 2ml tube. The transfection reagent was then added to the cells. Fifteen 
minutes prior to adding the transfection reaction mixture to the cells, they were 
disseminated in 500µl of culture medium in the 6-well plates. After adding 
transfection mixture to the cell suspension the , 6-well plates were shaken for about 
10 minutes to spread the cells evenly and to gain a consistent cell monolayer. The 
cells were incubated together with the transfection medium for 4 hours in the 
incubator at 37°C. During that time, the cells became adherent, permeabilized and 
absorbed the transfection reagent. After four hours of incubation the remaining 
transfection reagent was removed and replaced with normal culture medium. 
 
I.9.5.2  ShRNA transfection of adherent cells 
In accordance with the manufacturer’s protocol (Invitrogen), cells were seeded to a 6-
well plate the day before the transfection procedure. The experiment was performed 
in a 6-well plate. Each well consisted of 200,000 cells. 3µg of the shRNA plasmid 
was used. Lipofectamine 2000 (Invitrogen) and the calculated amount of shRNA 
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were diluted in 250µl Optimem medium (Invitrogen) and incubated separately for 5 
minutes at RT while being stored on ice. Afterwards, the content of the two collection 
tubes was mixed and incubated for another 20 minutes in a 2ml tube. The 
transfection reagent was then added to the cells and left for 4 hours. The transfection 
reagent was then discharged and the wells filled up with the culture medium. 
 
I.9.5.3  Monitoring transfection efficiency using florescence 
Alexa Fluor-labelled siRNA was used to check transfection efficiency. Transfection 
was performed as describe in the above. The amount of Alexa Fluor-labelled siRNA 
was adapted to the protocol. 1–100nM of Alexa Fluor-labelled siRNA was used for 
transfection in a 6-well plat containing 50,000 cells. Analysis was performed under 
the fluorescence microscope (Leica). Experiments were run using cells on day 2 after 
transfection.  
Efficient transfection in shRNA-transfected cells was monitored using a co-
transfection with a GFP-linked vector and the shRNA-expressing vector at a dilution 
of 1:4. Transfection was verified 2 hours after transfection under a fluorescent 
microscope (Leica). Transfection efficiency was determined by counting all cells in 
one visual field under bright field microscopy. The number counted was correlated to 
the number of cells counted in the same visual field under fluorescent microscopy. 
The transfection rate was quoted as a percentage.  
 
I.10 Protein 
I.10.1 Protein isolation techniques 
Different methods of protein isolation were tested to detect protein in western blot. 
First, RIPA buffer, one of the most reliable buffers, was used to lyse cultured 
mammalian cells, which enables protein to be extracted from cytoplasmic 
components, membrane and nuclear proteins. Before use, culture medium was 
removed from the cells, which were plated in a 6-well plate. Cells were washed twice 
with 5–7µl of PBS. Then 200µl of ice-cold RIPA buffer was added to each well. Cells 
detach from the bottom of the culture with slight pivoting. The suspension of RIPA 
and cells was transferred into a 2ml tube. The tubes with harvested cells were 
incubated for 15 minutes at 4°C in a shaking incubator. Then the tubes were 
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centrifuged for 10 minutes at 10,000 RPM and 4°C. The supernatant was stored in a 
new tube at -20°C or was analyzed in a BCA assay.   
The second protein isolation technique was performed using enzymatic digestion 
with Chondroitinase ABC. The enzyme Chondroitinase ABC digests GAG chains at 
37°C over a period of 2 hours. Chondroitinase ABC wass stored at -20°C and was 
slowly melted at RT before use. The enzyme solution was prepared based on 
SIGMA’s instructions. The product was reconstituted in a 0.01% bovine serum 
albumin aqueous solution. Subsequent dilutions were made into a buffer containing 
50mM Tris, pH 8.0, 60mM sodium acetate and 0.02% bovine serum albumin. All 
solutions were freshly prepared. Then 0.25 units of Chondroitinase ABC were 
incubated with the cell pellet of 20,000 cells. The cell lysates were incubated with 
Chondroitinase ABC with equal amounts 50µg of protein solution overnight at 37°C 
prior to loading onto western blot. Probes were analyzed in western blot. 
Thirdly, cells were harvested out of a 175m2 culture flask using the cell scraper. The 
cell monolayer was washed with 5–7ml of PBS. Subsequently, 2ml of PBS was 
added to the flask and cells were scraped off the bottom of the culture flask. The 
content of the culture flask was transferred into a tube and vortexed for 1 minute at 
10,000 RPM. The supernatant was then used for protein analysis. 
 
I.10.2 Immunprecipitation 
Immunprecipitation was performed to augment and enrich the content of the protein 
of interest in a sample. To that end, 200µl of G Sepharose was added to the 
supernatant of a 10ml culture flask and incubated at 4°C for 6 hours for pre-clearing 
in the overhead shaker. After centrifugation, the non-specifically bound G beads were 
discarded and the supernatant was incubated with the required antibody (e.g. 2 
mg/ml versican V0/V1 Neo-polyclonal antibody) at 4°C overnight. After washing, the 
beads were boiled in the protein loading dye for 5 minutes and loaded directly into 
the pre-poured Tris-HCl-glycine SDS–polyacrylamide gel electrophoresis (PAGE) 
gels (10%) along with pre-stained molecular weight standards (Bio-rad Laboratories, 
Palo Alto, CA, USA). Electrophoresis, blotting and blocking were performed as 
described below. The blocking was performed for 1 hour at RT with 5% non-fat 
freeze-dried milk and then incubated with 1mg/ml of the versican V0/V1 Neo-
antibody at 4°C overnight. Immune complexes were visualized using a horsedish 
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peroxidase-conjugated antibody followed by chemoluminescence reagent (Pierce 
Biotechnology). Manual film development was performed as described below. 
 
I.10.3 BCA assay 
The BCA protein assay was used to determine the concentration of proteins in 
samples. It was performed according to Uptima’s protocol using a BCA protein assay 
kit (Pierce/Uptima 23225) in a 96-well plate. The standard ranges between 0µg/ml 
and 2mg/ml of protein concentration. The samples were loaded in duplicate, diluted 
in aqua dest. at a ration of 1:4 and undiluted (Figure 7). Subsequently, a mixture of 
10µl reagent A and 200µl reagent B was added to each well. The plate was 
incubated for 30 minutes at 37°C. The absorbance of the formed BCA-copper-
chelate complex was detected using an ELISA-Reader at a wavelength of 540nm. 
The standard curve and sample values were analyzed using the Standard BCA 
software program called Softmax. 
 
A A blank Blank S1 S1 etc. 
200 Puffer A 
ug/ml 	  	  
B B - - S2 S2   
1000 
ug/ml 
C C - - S3 S3   
750 
ug/ml 
D D - - S4 S4   
500 
ug/ml 
E E - - S5 S5   
250 
ug/ml 
F F - -- S6 S6   
100 
ug/ml 
G G - - S7 S7   
20 
ug/ml 
H H - - S8 S8   
0 
ug/ml 
 
 Figure 7: Distribution of standard A-H and samples (S) in duplicate 
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I.10.4 Polyacrylamid gel electrophoresis 
SDS-PAGE stands for Sodium dodecyl sulphate (SDS) polyacrylamide gel 
electrophoresis (PAGE) and is a method used to separate proteins according to their 
size. After assembly of the gel apparatus (Biometra), the running and stacking gels 
were prepared. Solution components and percentages of gels consist of specific 
quantities of ingredients (Table 10). Water hoses were attached to the 
electrophoresis chamber to cool the apparatus.  
The running gel was filled into the gel apparatus and is immediately covered with 1ml 
of isopropanol for 30 seconds to burnish the surface of the gel. Next, isopropanol 
was discharged and the stacking gel poured on top of the running gel. A comb was 
placed adjacently. The comb was removed once the gel had hardened after 
approximately 20 minutes. The gel apparatus was fixed in an electrophoresis 
chamber and the chamber was filled with Tris/glycine/SDS running buffer (Biorad 
Laboratories) at a dilution of 1:10 with aqua dest.  
Samples were denaturized at 95°C for 5 minutes after adding Laemmli sample buffer 
(dilution 1:1) before loading. 10–30µg of a sample and 5µl of the molecular weight 
marker were loaded onto the gel. The electrophoresis was run at 160V until probes 
passed the stacking gel, then power was turned up to 180V. The run was stopped 
once the dye molecules reached the bottom of the gel.  
 
Solution  
components Running gel  
Solution  
components Stacking gel 
 6% 8% 10%  5% 
H2O 7.9 6.9 5.9 H2O 6.8 
30% acrylamide mix 3 4 5 30% acrylamide mix 1.7 
1.5M Tris (pH 7.8) 3.8 3.8 3.8 1.0 M Tris (pH 7.5) 1.25 
10% SDS 0.15 0.15 0.15 10% SDS 0.1 
10% ammonium 
persulfate 0.15 0.15 0.15 
10% ammonium 
persulphate 0.1 
TEMED 0.012 0.009 0.006 TEMED 0.001 
 
Table 10: Recipe for running gel and stacking gel 
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I.10.5 Transferring and visualizing the protein  
A semi-dry blot was performed to transfer and visualize the protein. A nitrocellulose 
membrane and 6 Whatman papers were cut to the estimated size of gel. Next, a 
nitrocellulose membrane and 6 Whatman papers were wetted in ice-cold transfer 
buffer for 5 minutes. Figure 8 shows the experimental set-up. Three Whatman papers 
were placed at the bottom of the blotting apparatus, followed by nitrocellulose 
membrane, gel and were covered with three Whatman papers. The cathode is placed 
on top and the blotting was started for 90 minutes at 80mA.  
The nitrocellulose membrane was stained with Ponceau red to check for sufficient 
and consistent protein transfer. The incubation time with Ponceau red lastes 5 
minutes on an agitator. Subsequently, the membrane was washed with aqua dest. 
until clear protein bands became visible. A colour photocopy was done for 
documentation purposes.  
 
 
 
Figure 8: Experimental set-up for blotting95 
 
I.10.5.1  Blocking and incubation with antibody 
In the next step, the membrane was blocked to avoid unspecific binding of the 
antibody. The blot membrane was therefore incubated on an agitator with 1.5% BSA 
in TBS-Tween for at least 30 minutes at RT. The blocking solution was discharged 
and the membrane shrink-wrapped with the antibody dissolved in TBS-Tween 
washing-buffer and incubated overnight at 4°C on an agitator. The antibodies were 
used in specific concentrations (Table 11).  
 
                             
                       
 
        Filter paper 
   
     
             SDS-page gel 
  
    
     Transfer membrane 
   
 
   Filter paper 
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Rabbit Anti-Versican V0/1 2µg/ml 
Rabbit Anti-Versican V0/2 2µg/ml 
ß-Actin mouse polyclonal 1µg/ml 
Horsedish peroxidase-
conjugated antibody 
1µg/ml 
 
Table 11: Concentrations of used antibodies 
 
After discharging the first antibody, the blot membrane was washed six times for 5 
minutes with TBS-Tween, followed by incubation with the second antibody at a 
dilution of 1:1000 in TBS-Tween for 1 hour. After that step, the blot membrane was 
again washed six times for 5 minutes with TBS-Tween. The antibody Rabbit Anti-
Versican V0/V1 Neo Polyclonal (BioReagent) and Antibody Rabbit Anti-Versican 
V0/V2 Neo Polyclonal (BioReagent) were used for western blotting.  
The Antibody Rabbit Anti-Versican V0/1 detects a ~70kDa protein representing 
versican from mouse cumulus oocyte complexes. The PA1-1748A immunogene is a 
synthetic peptide corresponding to residues CGGD(436) PEAAE(441) of human 
Versican V0/V1 Neo. The Antibody Rabbit Anti-Versican V0/V2 detects a 64kDa 
protein representing Versican V0/V2 Neo in human samples. The PA3-119 
immunogene is a synthetic peptide corresponding to residues CGGN(400), 
IVSFE(405) of human versican.96  
The tissue samples from mouse brain and cell pellets of glioma cell lines HTZ349, 
HTZ417, U87 and A172 were evaluated. Different isolation techniques were tested 
as described in the following. Western blot was performed using 20–50µg of the 
generated protein sample. The samples were loaded onto the gel mixed with sample 
buffer (Lammli) with or without beta-mercaptoethanol. The sample buffer was used at 
a dilution of 1:1. Samples were then denatured at 90°C for 5 minutes before loading. 
The samples were vortexed before and after heating. The protein was separated 
using SDS-PAGE and then transferred to nitrocellulose membrane for protein 
detection. 
 
I.10.5.2  Manual film development 
The ECL Kit (Sigma) was used as a substrate for colour development. The 
membrane was coated for 30–60 seconds with a mixture of 1ml of each solution. The 
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membrane was then placed in a developing chamber and covered with a film. Each 
film was exposed at three time points. The exposure time of a film varies between 3 
seconds, 1 minute and 5 minutes. As soon as the film was developed, the film was 
placed over the blot membrane and the marks of the size marker were transferred 
onto each film. 
 
I.10.5.3  Stripping 
The stripping solution was diluted at 1:20 in aqua dest. and incubated with the blot 
membrane for 20 minutes at RT. Next, the membrane was washed three times using 
TBS-Tween, each time for 10 minutes. Subsequently, the membrane was again 
blocked and incubated with another antibody or stored at -80°C for future 
experiments. 
 
I.10.6 Immunocytochemistry 
Immunocytochemistry is a method that helps to prove the expression of and to 
discover the localization of a protein/antigen of interest. Immunocytochemistry is 
especially used to determine the exact localization and place of progression of ECM 
molecules with specific antibodies.  
Immunocytochemistry was used in order to visualize the exact location of versican 
and its isoforms in the surrounding of the cell and cell surface. Therefore differing 
fixation methods were tested. PFA fixation permits cytoplasmic proteins to become 
visible. Methanol fixation was used to detect proteins on the nuclear side and the 
cytoplasm. 
Cells were seeded in 6-well plates on cover slips at least two days prior to fixation. 
For methanol fixation, culture medium was drained off and cover slips were rinsed in 
PBS. PBS was drained off and pre-cooled, and then 100% methanol was added at -
20°C for 10 minutes. After the fixation step, cover slips were washed three times for 5 
minutes. Cells were then permeabilized with 0.01% Triton X-100 in PBS for 30 
seconds and then again washed three times in PBS for 5 minutes. Cover slips were 
incubated in 1% BSA, PBS pH 7.5 for 30 minutes to block unspecific binding of the 
antibodies and then incubated with primary antibody in 1% BSA, PBS pH 7.5 for 60 
minutes at RT. After the cover slips were washed another three times with PBS, they 
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were incubated with the second antibody, Alfa-Rb Alexa 488. This fluorescent 
antibody is used in 1:1000 dilutions. Another washing step was performed. Prior to 
analyzing under florescence microscope, the cover slips were mounted in PPD-
mounting medium (90% glycerol) and sealed with nail polish. 
For PFA fixation, the medium consisted of 1.85g PFA, 3.5 ml dH2 and 10µl of 10M 
KOH. The fixation buffer was warmed to 37°C and added directly to cells after the 
culture medium was discharged and then fixed for 5–20 minutes. The washing and 
incubation steps with antibodies were performed as described in the above.  
 
I.10.7 Functional assays 
I.10.7.1  Proliferation assay 
In the proliferation assay, cells were harvested and counted 24 hours after 
transfection as described in the above. Five thousand cells per well were immediately 
seeded into a 12-well plate. Cell counts of each group (e.g. native cells, siRNA-
transfected cells and cells incubated with Lipofectamine) were defined at three to four 
time points (48 hours, 72 hours and 96 hours after transfection). Cell counting was 
performed as described in the above. The experiment was performed at least in 
triplicate and was repeated three times. Untreated cells, cells incubated with 
Lipofectamine, nonsense-siRNA-transfected cells and target-siRNA-transfected cells 
were used as control groups. The statistical analysis was performed as described 
below.   
 
I.10.7.2  Attachment assay 
The attachment assay was performed in a 96-well plate. Figure 9 shows the plate 
setting. Five thousand cells were seeded simultaneously five-fold to analyse three 
different time points. The first blank value containing 100µl of culture medium and a 
positive control containing 5,000 cells in 100µl culture medium per well were sown 
onto the 96-well plate five-fold. Then cell suspensions containing 25,000 cells/500µl 
of each investigated group were prepared and distributed across five tubes at a 
volume of 100µl per tube. 5x100µl of each group were seeded into a 96-well plate 
using a multi-pipette adjusted at 120µl. At predetermined time points (i.e. 10, 25 and 
45 minutes after seeding) cells were flushed three times with 100µl PBS. PBS was 
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discharged after the last washing step and replaced with 100µl of culture medium. 
Next, the well plate was put back into the incubator for 4 hours. Subsequently, wells 
were filled with 40µl of the XTT assay solution and incubated for another 2 hours. 
Quantitative analysis of the cells remaining in the culture plate was done by 
measuring photospectrometric absorption with an ELISA-Reader. A negative and 
positive control group served as reference values. The negative control group (BV) 
consisted of culture medium without cells, the positive control group (PC) comprised 
a distinct number of cells that dis not undergo flushing during the experiment.  
 
 
bv bv bv bv bv bv 
pc pc pc pc pc pc 
nat nat nat nat nat nat 
si-c si-c si-c si-c si-c si-c 
si-t si-t si-t si-t si-t si-t 
            
nat nat nat nat nat nat 
si-c si-c si-c si-c si-c si-c 
si-t si-t si-t si-t si-t si-t 
            
nat nat nat nat nat nat 
si-c si-c si-c si-c si-c si-c 
si-t si-t si-t si-t si-t si-t 
 
Figure 9: Test arrangement of 96-well plate in attachment assay. Bv = culture medium without 
cells, pc = culture medium containing 5,000 cells per well, nat = native cells, si-c = control- 
siRNA-transfected cells, si-t = target-siRNA-transfected cells 
 
I.10.7.3  Scratch assays  
The spreading and migration capabilities of cells were assessed using a scratch 
(wound) assay to measure the expansion of a cell population on a given surface. 
Cells were seeded into uncoated 6-well tissue culture dishes at a density of 100% 
confluence and cultured in culture medium containing 5% FCS. The cell monolayer 
was then scratched using a 100µl sterile pipette tip. The cellular debris was removed 
by flushing the cell monolayer with 500µl PBS. The wounded monolayer was then 
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incubated with 5% FCS medium for 48–72 hours. A grid was printed onto the culture 
dish and the wound area was inspected in marked fields at different time intervals 
until closure of the wound. The wound areas were photographed under a light 
microscope in defined rectangles created by the printed grid. The width of the scratch 
was measured at 6 and 12 hours after treatment. Thus, the cells that invaded the grid 
rectangle were counted. The number of invaded cells was correlated to the number 
of migrated cells in untreated control groups by statistical analysis. The experiments 
were run in triplicate and repeated at least three times. 
 
I.10.7.4  Boyden chamber 
The Boyden chamber assay, originally introduced by Boyden for the analysis of 
leukocyte chemotaxis, is based on a chamber of two medium-filled compartments 
separated by a microporous membrane measuring 8µm in diameter.  
Prior to starting the experiments, each cell population was grown in equal (80%) 
confluence in culture dishes under normal conditions. Cells were harvested as 
described in the above. The cell pellet was suspended in 200µl of DMEM and cell 
count was determined. The experiments were run with 5,000–10,000 cells per 
chamber. 
The Boyden chamber consists of two compartments. The lower chamber is 
separated from the upper chamber by a porous membrane (Figure 10). The lower 
chamber was filled with 110µl of fibroblast-conditioned medium (FCM). The 8µm 
mircoporous membrane was placed on top of the convex FCM fluid level, avoiding air 
bubbles. The membrane was fixed using the upper chamber’s screw cap. Then the 
cell suspension with a defined cell count was placed into the upper chamber. The 
experiments were done in triplicate. The chambers were returned to the incubator for 
4 four hours at 37°C. 
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Figure 10: Boyden chamber: Upper chamber filled with cell suspension; lower chamber filled 
with chemoattractant. Upper and lower chamber are separated by a porous membrane 
 
After the appropriate incubation time (4 hours), the fluid remaining in the upper 
chamber was discharged and the membrane carefully removed. The cells that were 
attached to the porous membrane were fixed and then stained with dye solution 
(Haemacolor). To that end the membranes were raised for 1 minute in a fixation 
medium and for 1 minute in dye solution 1 and 2. The stained membranes were then 
put on a glass slide and analyzed under a microscope. The cells were counted on the 
filter membrane under a microscope in three to five visual fields (Leica) and 
statistically analyzed using the ImageJ software. 
 
I.10.8 Statistical analysis 
Statistical analysis is performed in different experiments to substantiate results and 
determine their statistical significance and validity. In western blot and semi-
quantitative PCR, the results of particular products are visible as bands on blot 
membrane or under visualization in a Vilbert Lourmat chamber in agarose gel 
electrophoresis.  
To compare signal intensity, bands were scanned and underwent analysis using the 
ImageJ software. The images were opened using this software and measurements 
were set. The pictures needed to be inverted for signal intensity to be measured. 
Subsequently, the mean grey value, standard deviation modal grey value and 
median were defined. The ImageJ results were transferred to an Excel sheet; 
analysis involved comparing different treated cells with native and control samples 
(Microsoft Office Excel 2008). 
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In real-time PCR, the standard curve-based analysis is used. The standard curve 
values were generated from the data provided by the MxPro software, based on 
measured threshold cycle (Ct) values. Ct is defined as the number of cycles required 
for the fluorescent signal to cross the threshold (i.e. for it to exceed the background 
level). As Ct levels are inversely proportional to the amount of target nucleic acid in 
the sample,97 Ct-levels of a target gene were divided by the Ct levels of the 
housekeeping gene to obtain a normalized target value. Each of the normalized 
values was divided by the normalized control (untreated) sample value (Ct) to 
generate the relative expression levels. Table 12 gives an example of the calculation. 
 
Sample MV SD Calculated 
1/18sxsiV1 
CT-level 
18s 
 
1/18s 
CT-level 
siV1 
Native 1.28291 0.348339 0.904771 104.80 0.009541 94.82 
 
Table 12: Extract of an Excel table showing an example of calculated expression levels. MV = 
mean value, SD = standard deviation, calculated 1/18sxsiV1 = relative expression level in the 
sample  
  
In Boyden chamber assays, five visual fields per membrane were analyzed using the 
ImageJ cell counter tool. The experiments were carried out five-fold and repeated at 
least two times. The attachment assay was performed five-fold and repeated three 
times. The metabolic activity in compared groups was measured in the Elisa-Reader. 
The proliferation assay was performed four- to five-fold for each time point and 
repeated at least three times. The direct cell count provided the values for statistical 
analysis. In the scratch assay, the cells that invaded the grid were counted. At least 
four rectangles per well were counted. The experiments were done in triplicate.  
The mean value and the standard deviation of all experiments mentioned in the 
above were calculated with Microsoft Office Excel 2008. Student’s T-test was 
assessed in each experiment to compare values of treated cells with untreated cells 
or control groups (Figure 11).   
 
                   =T-test (Matrix1; Matrix2; page; type) 
 
Figure 11: Formula for Student’s T-test 
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Results 
I.11 Set up experiments  
The aim of this work was to investigate the influence of versican isoforms V1, V2 and 
V3 on cell motility, migration and proliferation ability. Specific siRNAs were used as a 
silencing tool. For quantitative analysis of my results and proof of successful 
transfection procedure, different methods had to be established before these 
methods could be applied to generate results. The challenges posed by and 
solutions found in regard to reverse transcriptase PCR (RT-PCR), quantitative real-
time PCR (qPCR), western blot and immunostaining will be described in the 
following. 
 
I.11.1 RT-PCR  
The first challenge in the PCR experiments was to design specific primers for 
versican isoforms V1, V2 and V3. Taking account of guidelines for primer design, 
primers were created that were capable for analysis in RT-PCR and qPCR. Primer 
pairs do not show complementary structures and potential to form secondary 
structures, for example hairpin structures. Runs of three or more Cs or Gs at the 3’-
ends of primers were avoided. The transcript of each primer pair matches the exon–
exon border sequence in the corresponding mRNA.  
Table 13 shows the primer sequences with their sense and antisense strands for 
each versican isoform. 
V0 Sense 5’GAC AGG TCG AAT GAG TGA TTT GAG 3  
 Antisense 5GCC ATT AGA TCA TGC ACT GGA TCT G 3’ 
      
V1 Sense 5’GAT GCC TAC TGC TTT AAA CGT CG3’  
 Antisense 5’GGT TGT CAC ATC AGT AGC ATT TGC3´  
      
V2 Sense 5’-TCACGACTTCAAGTCCTCCTGC-3’  
 Antisense 5’- GGTGCCTCCGTTAAGGCACG -3’   
      
V3 Sense 5’- GTGTGGAGGTGGTCTACTTGG-3’  
 Antisense 5’- GGTGCCTCCGTTAAGGCACG -3’   
 
Table 13: Primer sequences for versican isoforms V1, V2 and V3 
                                                                                                                           
   
 58 
The product length of the designed primers yields the requirements for analysis in 
quantitative PCR. The cDNA fragment of V1 generates a length of 228bp, the cDNA 
of V2 has a length of 208bp and the cDNA of V3 has a length of 154bp.  
To optimize PCR results, the individual annealing temperature for each primer pair 
and the amount of RNA was determined by gradient PCR. The following conditions 
were found to be suitable for primers targeting V1: the DNA polymerase was 
activated at 95°C for 5 minutes and amplified in 30 cycles at 95°C for 30 seconds, at 
66°C for 30 seconds, at 72°C for 30 seconds and was extended at 72°C for 5–7 
minutes. The PCR was run with 3µg RNA, with no further adjuvants. 
The best results in PCR with primers targeting V3 were achieved with 5µg RNA and 
an annealing temperature of 55°C. The product of V2 appeared faint or absent in all 
investigated cell lines. Thus, primer efficiency was enhanced with different adjuvants 
to the Master mix (e.g. Betaine, DMSO, formamide 5%, glycerol 10–15%, 
polyethylene glycerol 600 5–15 %). The best results were archived in the presence of 
1µl DMSO in 20µl Master mix for V2 and 3µl of RNA (Figure 12). Best results were 
seen at an annealing temperature of 45°C. 
 
 
 
Figure 12: Expression of the different isoforms of versican V1, V2 and V3 in malignant glioma 
cell lines (HTZ349, HTZ417, U87 and A172). The signal of V2 and V3 shows varying intensity in 
different glioma cell lines 
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   HTZ419 
 U87            
  A172 
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I.11.2 Quantitative PCR (qPCR) 
SYBR Green I, a fluorescent DNA-binding dye and a hot-start mediated Taq-
polymerase, was used in qPCR. An adequate thermal profile was established for 
primers V1 and V3. The hot-start Taq-polymerase was activated for 10 minutes at 
95°C in cycle 1, followed by 40 cycles in segment 2, comprising 1 minute at 95°C, 1 
minute at 62°C and 1 minute at 72°C. Segment 3 includes one cycle of 1 minute at 
95°C, 1 minute at 63°C and 30 seconds at 95°C. Further information on the function 
of my primers is provided in the analysis of the melting curves (Figure 13). For 
primers V1 and V3, the respective melting curves show a sharp peak on the 
estimated number of cycles, whereas the product of primers for V2 is not properly 
detectable (data not shown). 
 
 
Figure 13: Thermal profiles and melting curves in qPCR. The image on the left shows the 
thermal profile for primers targeting V1. The images on the right show the melting curve of V1 
(above) and 18s (below) 
 
I.11.3 Western Blot 
Western blot served the semi-quantitative analysis of specific protein expression in 
my experiments. Unfortunately, no antibody was available to detect versican isoform 
V3, which is why the analysis of its expression pattern is only based on the PCR 
results.   
At the beginning several difficulties were encountered in regard to the detection and 
identification of the protein band in western blotting (Figure 14). Different protein 
isolation techniques were therefore tested. The isolation of protein out of a cell lysate 
!
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using RIPA buffer generated multiple bands on the blot, which could not be assigned 
to a specific product of the antibody V0/1. Accordingly, different harvesting methods 
were examined (Figure 14). It became clear that in samples of culture medium 
containing FCS, antibody did not bind to the protein in a detectable amount, probably 
due to unspecific coverage of antigen epitopes. In culture medium samples without 
FCS, a clear protein band was detected, but unfortunately cells are not able to 
survive in culture medium without FCS for more than 6 hours. Therefore, the most 
efficient and reproducible method was to discharge the culture medium and carefully 
scrape off the cell monolayer from the bottom of the culture flask, adding PBS as 
described in the above. Western blot was run with the supernatant. It was 
demonstrated in further experiments that it was more efficient to load the protein 
samples under non-reducing conditions because, otherwise, when adding reducing 
agent ß-mercaptophenol the antibody V0/1 shows cross-binding. 
Further troubleshooting involved determining the blocking reagent. Best results were 
achieved when membrane blocking was performed using BSA 1.5 % dissolved in 
TBS-Tween.  
 
 
Figure 14: Results of a western blot with samples of 20µg protein of HTZ 349, incubated with 
antibody V0/1 using different protein isolation techniques. CM = culture medium, FCS = foetal 
calf serum, CM-FCS = culture medium without FCS, CM+FCS = culture medium with FCS, PBS 
= cells were harvested after adding PBS  
 
       HTZ349 CM+FCS 
   A172 PBS             
   HTZ349 CM-FCS 
         HTZ417 CM+FCS 
   HTZ349 PBS 
    HTZ417 PBS 
     HTZ417 CM+FCS 
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        64 kDa- 
       V1 
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In further experiments, different protein concentrations were tested. The best results 
were obtained using 20µg of protein (Figure 15). 
 
 
  
Figure 15: Western blot with HTZ349 and antibody V0/1 with different concentrations of protein 
(40µg, 30µg, 20µg)  
 
To generate more specific results, the protein concentration in the samples was 
enriched using immunoprecipitation. As described in the above, cell lysate was 
prepared to recover proteins in the supernatant. Protein G beads were saturated with 
the primary antibody V0/1, loaded and analyzed in western blot (Figure 16). The blot 
membrane showed a broad band at around 75kDa (the product is supposed to 
appear at around 70kDa) in all investigated samples. Signal intensity corresponded 
to the protein concentration.  
        64 kDa-         V1 
   HTZ349 40!g  
   HTZ349 30!g  
   HTZ349 20!g  
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Figure 16: Immunoprecipitation with antibody V0/1 in protein samples of HTZ349 and at 
different protein concentrations (10µg, 20µg, 30µg, 40µg and 50µg) 
 
I.11.4 Immunocytochemistry 
Immunostaining was performed to detect the localization of versican isoforms V1 and 
V2. The experiments were performed using the cell line HTZ349. The negative 
control was incubated only with the fluorescent antibody without addition of any 
targeting antibody. Some fluorescent signal was detected in all groups (Figure 17). 
The binding of antibody Neo V1/0 appears to capture all parts of the cell, especially 
the nucleus and extracellular matrix between two cells. The negative control showed 
strong enhancement of the cytoplasm and the central part of the cell. In the 
experiment with the antibody Neo V2/0, cells showed broad enhancement in the 
cytoskeleton with relief of the nucleus.  
 
        75 kDa-         V1 
   HTZ349 10!g  
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        50 kDa- 
        290 kDa- 
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Figure 17: PFA-fixation in HTZ349. Left: Negative control, fixated HTZ349 cells incubated with 
fluorescent antibody Alfa Rb-Alexa 488. Centre: HTZ349 incubated with florescence antibody 
Alfa-Rb Alexa 488 and antibody Neo V1/0. Right: HTZ349 incubated with florescence antibody 
Alfa-Rb Alexa 488 and antibody Neo V2/0 
 
In the cells fixated using methanol, the negative control showed only poor fluorescent 
emission. By contrast, cells incubated with antibody Neo V1/0 and Neo V2/0 showed 
rod-shaped enhancement in the cytoplasm and around the nucleus. Whilst antibody 
Neo V1/0 showed binding in the cytoplasm and nucleus, the antibody Neo V2/0 
appeared to accumulate in the area of the nucleus (Figure 18).   
 
 
Figure 18: Methanol-fixation in HTZ349. Left: Negative control, fixated HTZ349 cells incubated 
with fluorescent antibody Alfa-Rb-Alexa 488. Centre: HTZ349 incubated with florescent 
antibody Alfa-Rb Alexa 488 and antibody Neo V1/0. Right: HTZ349 incubated with florescent 
antibody Alfa-Rb Alexa 488 and antibody Neo V2/0 
 
 
PFA- fixation in HTZ349 
Negative control                                         Antibody Neo V1/0                                    Antibody Neo V2/0 
 
 
Methanol- fixation in HTZ349 
Negative control                                         Antibody Neo V1/0                                    Antibody Neo V2/0 
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I.11.5 SiRNA 
I.11.5.1  SiRNA design 
The mRNA sequence of the gene of interest was needed to design an siRNA and 
was retrieved from the NCBI database. In this context, it is important to remember 
that the structure of versican isoforms is a combination of different elements of V0 
(Figure 19).  
In V0, the G1- and G3-domain are connected by means of α- and ß-chains. V1 
contains G1-domain, ß-chain and G3-domain; V2 contains G1-domain, α-chain and 
G3-domain; and V3 contains G1- and G3-domain. As regards the structural 
homologies between V1, V2 and V3, siRNA target regions need to overlap in the 
bordering regions of the adjoining domains. As regards the mRNA sequence of V1, 
the crossing between G1-domain and ß-chain region was chosen for a proper target 
sequence as no other isoform shows a crossing area between the G1-domain and 
the ß-chain. The specific sequence for siRNA targeting V2 is supposed to be found in 
the crossing between the G1-domain and the α-chain. The target sequence for 
siRNA in the mRNA of V3 is localized at the junction between the G1- and the G3-
domain. 
 
 
 
Figure 19: Structure of versican isoforms. Alternative splicing of V0 generates V1, V2 and V398 
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The above- mentioned guidelines needed to be considered in the siRNA design. 
Finally, siRNA target sequences have a length of 21nt (Table 14). Regions within 50–
100bp of the start codon and the termination codon in mRNA had to be avoided. 
Even intron regions, stretches of four or more bases such as AAAA, CCCC, regions 
with GC content <30% or >60% were avoided, as these sequences generate binding 
problems in the target region.99 The sequences of the sense- and antisense-strand 
were blasted through the human genome using the NCBI database. Any homologies 
of the chosen siRNA sequences to other human gene sequences were ruled out. 
  
 Target 5’-GGG AGU UCU UCG AUU CCA ATT-3’ 
V1 Sense 5’-r(GGG AGU UCU UCG AUU CCA A)dTdT 
 Antisense 5’-r(UUG GAA UCG AAG AAC UCC C)dTdT 
 
 Target 5’- AGA AAA TAA GAC AGG ACC TGA- 3’ 
V2 Sense 5’-r(AAA AUA AGA CAG GAC CUG A)dTdT 
 Antisense 5’-r(UCA GGU CCU GUC UUA UUU U)dCdT 
 
 Target 5’-TAC TGC TTT AAA CGA CCT GAT-3’  
V3 Sense 5’-r(CUG CUU UAA ACG ACC UGA U)dTdT 
 Antisense 5’-r(AUC AGG UCG UUU AAA GCA G)dTdA 
 
Table 14: Target sequences in mRNA of V1, V2 and V3, including sense- and antisense-strand 
of siRNAs 
  
The negative control was designed by scrambling the target-siRNA sequence. The 
control RNA had the same length and nucleotide composition as the siRNA, but had 
at least four to five bases mismatched to the siRNA. Further, it was ruled out that the 
scrambled siRNA was able to create new homology to other genes.  
 
I.11.5.2  siRNA transfection 
Set up experiments for siRNA transfection in HTZ349, HTZ417, U87 and A172 were 
started with the transfection reagent Lipofectamine plus (invitrogen) and siRNA 
targeting MAPK and non-silencing, Alexa Fluor-labelled negative control siRNA. As 
under Lipofectamine plus, most of the cells looked highly impaired when their cell 
shape was examined under the microscope and died during the transfection 
procedure even at lower concentrations (2µg, 1.5µg and 1µg) of Lipofectamine. The 
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transfection reagent was thus changed to Lipofectamine 2000 and the transfection 
medium Optimem was used. Under these new conditions, the vitality and survival 
rate of the cells improved.  
The transfection efficiency rate was determined by analyzing Alexa Fluor-labelled 
negative control siRNA (data not shown). 
 
I.11.5.3  Creating shRNA  
As the results of the experiments with siRNA targeting V1 necessitated further long-
term investigations, for example in animal assays, a short hairpin transfection system 
was established. The silencing effect of siRNA transfection is a transient effect lasting 
several days, which means a limitation of siRNA use in functional assays lasting 
longer than four days. For that reason I decided to operate a stable and inducible 
system of RNAi, so-called short hairpin RNA (shRNA). The following sequences for a 
short hairpin construct were chosen (Table 15). 
 
mRNA sequence 5’ GGG AGU UCU UCG AUU CCA ATT ‘3 
Top sequence 5’GATC CCC GGG AGT TCT TCG ATT CCA TTCAAGAGA AAT TGG AAT 
CGA AGA ACT CCC TTTTT GGAAA ‘3 
Bottom sequence 5’AGC TTTCC AAAAA GGG AGT TCT TCG ATT CCA ATT TCTCTTGAA 
AAAT TGG AAT CGA AGA ACT CCC GGG ‘3 
Duplex  3’GATC CCC GGG AGT TCT TCG ATT CCA ATT TTCAACACA AAT TGG 
AAT CGA AGA ACT CCC TTTTT GGAAA GGG CCC TCA AGA AGC TAA 
GGT TAA AAGTTCTCT TTA ACC TTA GCT TCT TGA GGG AAAAA 
CCTTTTCGA _5 
Table 15: Top sequence: GATC served as the BGL II cutting site in the top sequence, CCC 
represented the spacer followed by sense-, loop- and antisense sequence, termination signal 
TTTTT GGAAA and spacer CCC. The Hind III cutting site is located in the palindromic sequence 
in the reverse and bottom sequence.  
 
The plasmid has a RNA Polymerase III-dependent promoter and a terminator signal 
for the transcript area (5 Ts one after another). The sequence of siRNA targeting V1 
was ligated into the pENTR-THT vector. After transcription of the vector sequence, 
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the RNA was folded into a hairpin-like structure, which is a substrate for the enzyme 
Dicer and leads to cellular production of the siRNA.  
The experiments were run with co-transfection of fluorescent markers like GFP and 
PDS Red to analyze transfection efficiency. Figure 20 shows GFP and shV1 co- 
transfection in HTZ349 under the fluorescence microscope and the same slice under 
the bright field microscope. The photographs were taken 24 hours after transfection.  
 
 
 
Figure 20: GFP and shV1 co-transfection in HTZ349 under the fluorescence microscope (left) 
and the same slice under the bright field microscope (right).   
 
Figure 21 shows the transfection efficiency in GFP-transfected cells, cells co-
transfected with an empty control GFP-containing vector and cells co-transfected with 
shRNAV1 and GFP. Subtracting the bright field image and fluorescence image 
revealed a transfection efficiency of 36% in GFP-transfected cells, 29% cells co-
transfected with an empty control vector GFP and 35% in cells co-transfected with 
shV1 and GFP.  
Despite the poor transfection efficiency, the results in western blot showed a clear 
alleviation of the band of V1 in shV1-transfected cells, although a mild alleviation of 
control vector transfected cells was observed. In the blot that was incubated with the 
antibody targeting V0/2, the expression pattern of V2 did not change. Ponceau 
staining of the blot membrane showed equal protein loading in all samples.  
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Figure 21: Western blot with GFP-transfected cells (GFP vector), cells co-transfected with an 
empty control vector GFP (GFP control + sh-control) and cells co-transfected with sh-RNA 
targeting V1 and GFP (GFP vector + shV1) 24 hours after transfection. Antibody V0/1 and V0/2, 
Ponceau staining 
 
 
 
Figure 22: Statistical analysis of western blot results with harvested cells of the same 
experiment with antibody V0/1 (above) and V0/2 (below) with Ponceau staining as marker   
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I.12 Transfection with siV1, siV2 and siV3 
The transfection efficiency in all experiments was monitored on the protein and PCR 
level. Control groups in the experiments consisted of cells incubated with 
Lipofectamine only, nonsense-siRNA transfected cells (si-control) and native cells 
(native). These control groups helped to assign whether changed cell behaviour, 
especially in functional assays, was due to side effects of the transfection procedure 
or could be regarded as a specific effect of the siRNA. Mitochondrial 18s was chosen 
as the housekeeping gene, as it is present in all nucleated cells types. The mRNA 
synthesis of these genes was considered to be stable and secure in various tissues, 
even under experimental treatment.100  
 
I.12.1 Semi-quantitative analysis of siv1 transfection in RT-PCR 
In real-time PCR, cDNA of different cell lines HTZ349, HTZ417, U87 and A172 were 
analyzed at different time points after transfection. Assays were repeated at least two 
times in each cell line. Native cells, nonsense siRNA-transfected cells and siV1-
transfected cells were harvested 24 hours and 48 hours after seeding and analyzed 
in PCR with primers targeting V1.  
A strong down-regulation of V1 expression in HTZ349 on days 1 and 2 after 
transfection was detected. In samples harvested on day 2 after transfection, a slight 
increase in signal was seen in siV1-transfected cells. Both control groups, nonsense 
siRNA-transfected cells and native cells, showed strong signal, whereupon a slight 
regulation of V1 expression was assumed in nonsense siRNA- transfected cells 
(Figure 23).  
 
  
Figure 23: Results of RT-PCR with HTZ349 after transfection with siRNA targeting V1 on day 1 
with primers targeting V1 and 18s 
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     V1 
     18s 
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Equal loading of RNA in RT-PCR and cDNA in electrophoresis is proven in analysis 
with primers targeting the housekeeping gene 18s. The housekeeping gene 
expression showed consistent bands in all samples (Figure 23). 
The down-regulation effect of siV1 was visible within the first three days after 
transfection (Figure 24). On days 4 and 5 the signal of V1 in siV1-transfected cells 
became nearly as strong as in native cells and control groups. No regulatory effect 
was seen in the controls groups (Lipofectamine-incubated cells and nonsense 
siRNA-transfected cells) compared with native cells. Equal signal intensity in the 
native sample and control groups was maintained on days 3, 4 and 5 after 
transfection (data not shown). 
 
 
 
Figure 24: Results of RT-PCR with HTZ349 after transfection with siRNA targeting V1 on days 1, 
2, 3, 4 and 5 with primers targeting V1 and 18s. Control groups: native cells, Lipofectamine 
treated cells and control siRNA transfected cells 
 
As regards the possibility of off-target effects in siRNA transfection, PCR was run 
with primers targeting V2 and RNA samples of native cells, nonsense siRNA-
transfected cells and siV1-transfected cells (Figure 25). The product of versican 
isoform V2 on estimated length appeared in none of the samples. The bands at the 
bottom of the gel were interpreted as primer dimers. The same samples were used 
for a PCR run with primers targeting V3 (Figure 25). The product appeared in the 
estimated length. No regulatory effect of V3 was seen in any of the samples, 
especially not in the sample comprisingsiV1-transfected cells. 
The results were replicated in cell lines HTZ417 (Figure 26), U87 (Figure 27) and 
A172 (Figure 28) at two to three different time points (data not shown).  
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Figure 25: RT-PCR with HTZ349, transfected with siV1 and primer V2, V3 and 18s       
 
 
 
Figure 26: RT-PCR with HTZ417 and primers targeting V1 and 18s. Cells were transfected with 
si-control, siV1 and siV3       
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Figure 27: RT-PCR with U87 and primers targeting V1 and 18s. Cells were transfected with siV1, 
si-control and Lipofectamine    
 
 
 
Figure 28: RT-PCR with A172 and primers targeting V1 and 18s. Cells were transfected with 
siV1 and si-control    
                                                            
I.12.2 Semi-quantitative analysis of siV2 transfection in RT-PCR 
Figure 29 shows the results of a PCR with native cells, siV2- and siV3-transfected 
cells using primers detecting V1, V2, V3 and 18s. The first image confirms equal 
cDNA loading on the PCR level, as the expression of the housekeeping gene 18s 
showed consistent signal intensity in all investigated cell populations. The analysis of 
the product in PCR with primers detecting V1 showed a complete suppression of V1 
in siV2- and V3-transfected cells. By contrast, the product V2 appeared on the PCR 
     18s 
PCR, U87 
    native 
      si- control 
    si- V1 
 Lipofectamine 
     V1 
  228 bp- 
   200 bp- 
     18s 
PCR, A172 
    native 
      si- control 
    si- V1 
     V1   228 bp- 
   200 bp- 
    native 
si- control 
    si- V1 
                                                                                                                           
   
 73 
level on the estimated length in native cells, siV2- and siV3-transfected cells. 
Compared with native cells, the expression of V2 appeared to be decreased in siV2-
transfected cells, but still detectable. PCR results with primers targeting V3 in the 
same samples did not show any obvious regulation of V3 expression in siV2-
transfected cells. 
 
I.12.3 Semi-quantitative analysis of siV3 transfection in RT-PCR 
In the experiment using siV3 transfection, RT-PCR showed a mild regulation of V3 in 
siV3-transfected cells (Figure 29). Off-target effects were examined in the same 
samples and with primers targeting V1 and V2. The PCR results showed a complete 
suppression of product V1 in cells treated with siV3. Control runs with primers 
targeting V2 also showed regulation of V2 in siV3-transfected samples. The PCR with 
primers targeting 18s confirmed equal cDNA loading. 
 
 
 
Figure 29: RT-PCR with HTZ349 and two different samples of native cells, siV2- and siV3-
transfected cells with primers for 18s, V1, V2 and V3 
 
I.12.4 Quantitative PCR in siV1-transfected cells 
In quantitative PCR, versican isoform V1 was amplified and simultaneously 
quantified. The analysis was based on standard curve method as described in the 
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above. 18s was again used as the housekeeping gene. Native samples and siV1-
transfected cells were compared. 
The standard curves contain squares that exposed the range of cDNA dilution series 
set in duplicate. A triangle symbol marks the concentration of cDNA in the samples, 
which were analyzed in a dilution of 1:20. The diagram shows the standard curve for 
the product 18s and for the product V1. All samples needed to lie within the standard 
dilution series values for valid analysis (data not shown). 
For analysis, the target gene value was divided by the reference gene value. The 
ratio of target gene values was obtained in relation to the control sample and was 
corrected with the values of our reference gene. According to the findings in RT-
RCR, siV1-transfected cells showed a massive decrease in V1 expression in 
comparison to native cells on the qPCR level (Figure 30). The nearly complete down-
regulation of V1 was definitively proven on day 1 (p = 0.03) and on day 2 (p = 0.022) 
after transfection, and was less distinctive on day 3 after transfection (p = 0.28) 
according to the results obtained in RT-PCR. Figure 31 shows the down-regulation of 
V1 in HTZ419 on day 1 (p = 0.03) and on day 2 (p = 0.03) after transfection, and was 
less significant on day 3 after transfection (p = 0.107). 
Subsequently, the same samples were analyzed in RT-PCR with primers targeting 
V3 to exclude off-target effects. Experiments showed that there was no significant 
influence on the expression pattern of V3 obtained in siV1-transfected cells on days 
1, 2 and 3 after transfection. Unfortunately, primers targeting V3 could not be 
established in qPCR.  
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Figure 30: Quantitative PCR results of siV1-transfected in A172. The analysis compared the 
product of primers targeting V1 in native and siV1-transfected cells. * p = 0.028 
 
 
  
 
 
Figure 31: Quantitative PCR results of siV1-transfected in HTZ417. The analysis compared the 
product of primers targeting V1 in native and siV1 transfected cells. * p = 0.107 
 
I.12.5 Protein regulation 
After successful down-regulation of isoform V1 in siV1-transfected cells on the PCR-
level, the expression of V1 on protein level was investigated. Protein harvesting was 
performed as described in the above. The experiments were run with a protein 
concentration of 20µg for each sample. Ponceau staining was used to control equal 
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protein loading. A regulatory effect of siRNA-targeting V1 was seen in the decreased 
expression of protein V1 in western blot (Figure 32, Figure 33). The same samples 
were analyzed with antibody V0/2. An off- target regulation of V2 in siV1-transfected 
cells was ruled out (Figure 34). Reference groups again consistened of cells 
incubated with Lipofectamine and nonsense-siRNA transfected cells (si-control). 
Interestingly, the expression of V1 in native and Lipofectamine-transfected cells 
appeared to remain nearly equal, whereas the si-control-transfected cells showed a 
clear decrease in V1-expression (Figure 33).  
 
 
Figure 32: Results of western blot in HTZ349, transfected with siV1. Western blot was 
performed with antibody V0/1 and V0/2  
        64 kDa- 
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Figure 33: Statistical analysis of western blot results in HTZ417 transfected with siV1. Western 
blot was performed with antibody V0/1 
 
 
Figure 34: Statistical analysis of western blot results in HTZ417 transfected with siV1. Western 
blot was performed with antibody V0/2  
 
Further, an analysis of protein expression of V1 and V2 in siV2- and siV3-transfected 
cells was determined in western blot using antibody V0/1 and V0/2. Figure 35 shows 
the stable expression of V1 in si-control-transfected cells compared with siV2- and 
siV3-transfected cells. Findings on the PCR level, which showed a decreased level of 
cDNA V1 in siV2-transfected cells, could not be confirmed on the protein level. 
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HTZ349 (Figure 33), the expression level of V1 in si-control-transfected cells was 
decreased compared to native cells (Figure 35). 
Analysis of siV2- and siV3-transfected cells with antibody V0/2 showed no visible 
impairment of V2 and V3 expression on the protein level (Figure 36). These findings 
confirm observations under the PCR analysis (Figure 29).  
 
 
Figure 35: Statistical analysis of western blot results in HTZ349 transfected with siV2 and siV3. 
Western blot was performed with antibody V0/1 
 
 
 
Figure 36: Statistical analysis of western blot results in HTZ349 transfected with siV2 and siV3. 
Western blot was performed with antibody V0/2  
 
 
0 
20000 
40000 
60000 
80000 
100000 
120000 
140000 
160000 
180000 
D
en
si
ty
 in
 p
ix
el
 
Western blot, HTZ349, Ab V0/1 
 
0 
50.000 
100.000 
150.000 
200.000 
250.000 
300.000 
350.000 
D
en
si
ty
 in
 p
ix
el
 
Western blot, HTZ349, Ab V0/2 
 
                                                                                                                           
   
 79 
I.12.6 Proliferation assay 
I.12.6.1  Proliferation assay for siV1-transfected cells 
The cell proliferation assay was performed using native cells, Lipofectamine-
incubated cells, control siRNA-transfected cells and siV1-transfected cells. In the 
experiment, 10,000 cells were seeded per well and counted on days 1, 2, 3, 4, 5, 6 
and 7. Cell count on day 1 was halved in all investigated groups (Figure 37, Figure 
39). In HTZ349 all cell populations showed a proliferation stop within the first two 
days of the experiment. On day 3 to 4r, native cells, Lipofectamine-incubated cells 
and control siRNA-transfected cells started to proliferate nearly in the same manner, 
whereas the population of si-control-transfected cells seemed a little less active 
(Figure 37). The proliferation rate of siV1-transfected cells was significantly lower 
than in si-control-transfected cells on day 5 (p < 0.001) and on day 7 (p = 0.005) in 
the experiment. As measured by cell count on days 4 and 7, cell count was increased 
7.6-fold in nonsense siRNA-transfected cells and 6.6-fold in siv1-transfected cells. 
These findings were reconfirmed in an analysis of cell lines HTZ419 and U87. The 
strongest effect was seen in the cell line U87 on day 3 (p = 0.002).  
 
 
 
Figure 37: Proliferation assay with HTZ349. Starting point: 24 hours (d0) after transfection. 
10,000 cells per group were placed in triplicate in a 12-well plate and harvested and counted on 
days 1, 2, 4, 5, 6, 7 after transfection. *p = 0.005 (si-control to siV1 on day 7), p < 0.001 (si-
control to siV1 on day 5) 
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Figure 38: Proliferation assay with HTZ417. Starting point: 24 hours (d0) after transfection. 
10,000 cells per group were placed in triplicate in a 12-well plate and harvested and counted on 
days 1, 2 and 4 after transfection. *p = 0.01 (si-control to siV1 on day 7) 
 
  
 
Figure 39: Proliferation assay with U87. Starting point: 24 hours (d0) after transfection. 10,000 
cells per group were placed in triplicate in a 12-well plate and harvested and counted on days 
1, 2, 3 after transfection. *p = 0.002 (si-control to siV1 on day 7) 
 
  
The RNA content of harvested cells from these experiments was analyzed in semi-
quantitative PCR. The results showed nearly complete suppression of V1 within the 
first three days. On days 4 to 7 a product of V1 was again visible on the PCR level.  
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I.12.6.2  Proliferation assay for siV3-transfected cells 
Proliferation assays were repeated under the same conditions with cells transfected 
with siRNA targeting V3. All groups showed the same proliferation ability (Figure 40). 
After a slight decrease in cell population within the first day, the proliferation rates of 
all groups including siV3-transfected cells developed normally without significant 
changes. Cell count increased in all groups about 3.1-fold on day 5. There was no 
statistically significant change to be seen in the proliferation rate of siV1-transfected 
cells compared to si-control-transfected cells (p = 0.085). 
 
 
 
 
Figure 40: Proliferation assay of HTZ349 in siV3-transfected cells. Cells were harvested and 
counted on days 3, 5 and 8. *p = 0.085 
 
I.12.7 Attachment assay 
In the test run of the attachment assay with all cell lines it was observed that HTZ349, 
HTZ417, U87 and A172 showed different attachment behaviour in cell culture. Thus, 
the time to attachment to the culture dish after seeding was determined for each cell 
line prior to starting with experiments. A172 cells began to attach to the culture plate 
15 minutes after seeding. HTZ349 and HTZ417 attached within the first 30 minutes 
and U87 attached after 20 minutes. The experiments were performed as described in 
the above. Experiments were run with native cells, Lipofectamine-treated cells, 
control siRNA-transfected cells and siRNA- transfected cells. 
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I.12.7.1  Attachment assay for siV1-transfected cell  
In the attachment assay with HTZ349, no significant changes were seen in the 
attachment behaviour of siV1- and si-control-transfected cells compared to the other 
cell populations. Even the extended observation period up to 60 minutes showed the 
same results (Figure 41, Figure 42). These findings were confirmed in the attachment 
assay with cell lines HTZ419 and A172 (Figure 43 – Figure 46). 
 
 
Figure 41: Attachment assay with HTZ349 and siV1-transfected cells. Experiments were run 
with 5,000 cells per well five-fold for each group. Analysis was performed 40 minutes after 
seeding. *p = 0.36 
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Figure 42: Attachment assay with HTZ349 and siV1-transfected cells. Experiments were run 
with 5,000 cells per well five-fold for each group. Analysis was performed 60 minutes after 
seeding. *p= 0.45 
 
 
 
Figure 43: Attachment assay with HTZ419 and siV1-transfected cells. Experiments were run 
with 5,000 cells per well five-fold for each group. Analysis is performed 25 minutes after 
seeding. *p = 0.48 
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Figure 44: Attachment assay with HTZ419 and siV1-transfected cells. Experiments were run 
with 5,000 cells per well five-fold for each group. Analysis was performed 40 minutes after 
seeding. *p = 0.24 
 
 
 
Figure 45: Attachment assay with A172 and siV1-transfected cells. Experiments were run with 
5,000 cells per well five-fold for each group. Analysis was performed 25 minutes after seeding. 
*p = 0.45 
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Figure 46: Attachment assay with A172 and siV1-transfected cells. Experiments were run with 
5,000 cells per well five-fold for each group. Analysis was performed 40 minutes after seeding. 
*p = 0.44 
 
I.12.7.2  Attachment assay for siv3-transfected cells 
The attachment assay was performed with siV3-transfected cells in the same settings 
as described in the above (Figure 47, Figure 48). At 20 minutes no difference in the 
attachment behaviour was observed. At 40 minutes, native and Lipofectamine-
treated cells showed an increase in cell number, whereas the number of si-control- 
and siV3-transfected cells remained the same. A statistically significant value could 
not be proven between si-control- and siV3-transfected cells.   
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Figure 47: Attachment assay with HTZ349 and siV3-transfected cells. Experiments were run 
with 5,000 cells per well five-fold for each group. Analysis was performed 20 minutes after 
seeding. *p = 0.25 
 
 
 
Figure 48: Attachment assay with HTZ349 and siV3-transfected cells. Experiments were run 
with 5,000 cells per well five-fold for each group. Analysis was performed 40 minutes after 
seeding. *p = 0.14 
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I.12.8 Migration assays 
I.12.8.1  Scratch assay 
The scratch assay was used as a two-dimensional migration assay, which is 
compatible with microscopy including live cell imaging.101 Comparing the tracks of 
differently treated cells under the same experimental conditions allows the role of V1 
in the regulation of directional cell migration to be determined. Figure 49 (left) shows 
nearly 100% confluent growing native cells, si-control transfected and siV1-
transfected cells with a freshly made scratch.  
 
 
 
Figure 49: Scratch assay with HTZ419. The images were taken using a bright field microscope 
directly after placing the scratch (d0) and on day 2 (d2). Left: native cells, si-control-transfected 
cells and siV1-transfected cells immediately after placing the scratch on day 0. Right: migrated 
cells on day 2 
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The optimal experimental set-up for the scratch assay was determined observing 
different time points after seeding (12h, 24h, 36h and 48h). After two days, the cell 
population assembled with cells of the opposite side of the scratch. Statistical 
evaluation of migrated cells in the group of native cells, si-control-transfected cells 
and siV1-transfected cells showed impaired migratory activity in all treated cell 
populations. Additionally, siV1-transfected cells showed a further decrease in their 
migration rate, which is statistically highly significant (p < 0.001) in comparison to the 
si-control-transfected cells in cell lines HTZ349 and HTZ419 (Figure 50, Figure 51). 
In U87, a decreased migration rate was seen in siV1-transfected cells and si-control-
transfected cells with a p value of 0.014 (Figure 52). 
 
  
 
Figure 50: Statistical analysis of migrated cells in scratch assay with siV1-transfected HTZ349 
cells. *p < 0.001 
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Figure 51: Statistical analysis of migrated cells in scratch assay with siV1-transfected HTZ417 
cells. *p < 0.001 
 
 
 
Figure 52: Statistical analysis of migrated cells in scratch assay with siV1-transfected U87 
cells. *p = 0.014 
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The analysis of siV3-transfected cells in HTZ349 showed no changes in the migration 
behaviour of transfected cell populations compared to untreated cells (Figure 53).  
 
 
 
Figure 53: Statistical analysis of migrated cells in scratch assay with siV3-transfected HTZ349 
cells. *p < 0.43 
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I.12.8.2  Boyden chamber assay 
The Boyden chamber assay was performed for the three-dimensional analysis of the 
migratory ability in glioma cells. This allowed an analysis of cell migration separately 
from cell–cell interaction and proliferation.102 As already demonstrated in the scratch 
assays described in the above, the results of the Boyden chamber assay confirmed 
the decrease in the migratory ability of siV1-transfected cells (Figure 55). Figure 54 
shows the porous membrane at the end of the experiment. SiV1-transfected cells 
showed, in comparison to nonsense siRNA-transfected cells, a significant limitation in 
their migration ability (p = 0.001) in HTZ349 and in HTZ417 (Figure 56). 
 
 
 
Figure 54: Boyden assay with HTZ349. Migration time: 4 hours. The experiment was run with 
native cells, si-control-transfected cells and siV1-transfected cells  
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Figure 55: Statistical analysis of migrated cells in Boyden assay with siV1-transfected HTZ349 
cells. *p = 0.001 
 
 
Figure 56: Statistical analysis of migrated cells in Boyden assay with siV1-transfected HTZ417 
cells. Migration time: 4 hours. *p = 0.001  
 
In the Boyden assay with siV3-transfected cells (Figure 57, Figure 58), siV3-
transfected cells showed a mild increase in migrated cells compared with native cells, 
though this was without statistical significance. Also, the decrease in migrated cells in 
control siRNA-transfected cells showed no statistically significant results (p = 0.27). 
When the experiment was repeated again, the results remained with no significant 
change in migration ability compared with native cells.   
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Figure 57: Statistical analysis of migrated cells in Boyden assay with siV3-transfected HTZ349 
cells. Migration time: 4 hours. *p = 0.27 
 
 
 
Figure 58: Statistical analysis of migrated cells in Boyden assay with siV3-transfected HTZ417 
cells. Migration time: 4 hours.  
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Discussion 
This thesis was able to show that siV1, but not siV3, significantly decreases the 
migration of glioma cells lines. This inhibition of migration is not attributable to the 
increased attachment of cells, one of the steps in tumour cell invasion. In addition, 
siV1 decreased proliferation in glioma cell lines. I therefore postulate that the 
versican isoform V1, but not V2 or V3, is an essential modulator of glioma cell 
migration and proliferation. 
Extracellular matrix plays an important role in the aggressiveness of cancers, as it 
induces changes in cellular attachment, motility, invasion and proliferation. It is a 
well-known fact that versican has an increased expression level in cancer. Based on 
this and taking account of the results mentioned in the introduction, I planned to 
address the function of versican isoforms in malignant glioma cell lines.103  
The isoforms of versican are found in various tissues and tumour cells. Previous 
publications and results from our laboratory already suggested that the isoforms of 
versican show different expression patterns, which might translate into different 
functions of the isoforms.104 It has been reported that isoforms V0 and V1 are 
predominant forms in malignant glioma cells,105 a finding that was reconfirmed in this 
work. The isoforms V0, V1, V2 and V3 were detected in all investigated cell lines 
(HTZ345, HTZ417, U87, A172) on the RNA level.  
The proof of isoform V1 was easy, as it is described as the predominant isoform in 
glioma cell lines. The proof of V2 on PCR level did not succeed very well. It has ben 
reported that V2 is a major constituent of adult brain ECMs and has a characteristic 
expression pattern in myelinated fibre tracts of the CNS,106,107 whereas the 
expression in glioma cells lines appears to be very low level.108 The results of semi-
quantitative PCR in this work confirmed the varying expression pattern of V2 in all 
cell lines used.  
Only little information is available on the function of versican isoform V3 in glioma cell 
lines. Previously, isoform V3 was detected in activated endothelium, in arterial 
smooth muscle cells and melanoma cancer cells.109 In view of the fact that V3 might 
play a dual role as an inhibitor of tumour growth and a stimulator of metastasis in 
melanoma cancer cells, it would be interesting to establish which role V3 might play 
in glioma cell lines.110 Isoform V3 was detected on the semi-quantitative and 
quantitative PCR level in all investigated glioma cell lines, mandating an examination 
of its function. 
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Providing evidence of V1 on the protein level is a challenging task. V1 did not appear 
on the estimated protein lengths of 70kDa in western blots under current protein 
isolation techniques (Figure 14, Figure 15). Instead, I found various bands on the blot 
and it was not possible to clearly attribute the correct product. In literature different 
variants of harvesting methods and sample preparation before the run are described, 
i.e. some authors said that the digestion of a protein sample with Chondroitinase 
ABC would remove chondroitin side chains of V1 and might improve antibody 
binding. Despite implementing this method knowing that alternative splicing in the 
extracellular space generates the isoforms of versican, results still remained 
unsatisfactory. New harvesting methods were tested consecutively in order to 
increase the yield of pure protein. However, even protein augmentation via 
immunoprecipitation remained ineffective. Imagining a dissociation of versican 
isoforms from the cell to the surrounding culture medium led to the idea of that 
protein could be isolated from the culture medium. As it was impossible to isolate 
protein V1 and V2 out of FCS-containing medium, it is suggested that FCS covers 
binding sites of versican and consequently disables antibody binding. Further, the 
protein might stay attached to the bottom of the culture flask. Constant results in 
western blot were gained when the protein was scraped off the bottom of the culture 
flask and separated from the cell debris. 
Both harvesting methods were tested in western blot using the antibody for V2. 
Analysis of samples consisting of cell lysate and samples, which were harvested 
using the method described for V1 isolation, also worked. The different expression 
patterns and difficulties inherent in the protein isolation of V1 and V2 raised questions 
concerning the exact localization of these proteins. To clarify the predominant 
position of V1 and V2 in the context with the cell surface or cytoplasm, 
immunostaining was performed with the same antibodies that were used in western 
blotting experiments. Methanol fixation detected the relevant proteins on the nuclear 
side and in the cytoplasm.  
Under PFA fixation it became clear that the negative control consisting of cells 
incubated with fluorescent antibody only showed some fluorescent signal under the 
microscope. As in PFA fixation, cell walls remained intact, and unspecific binding of 
the fluorescent antibody on the cell surface of the negative control was proposed. 
Cells incubated with antibody Neo V1/0 and V2/0 showed a stronger signal across 
their whole surface and on the connection site with neighbouring cells. In contrast, in 
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the experiment with methanol fixation, there was a clear, vesicle-like formation visible 
in the cytoplasm of cells incubated with antibody Neo V1/0 (Figure 18). In contrast, in 
cells incubated with the antibody Neo V2/0, the nucleus showed a strong fluorescent 
signal, whereas no vesicles could be detected in the cytoplasm. This observation 
suggests that V1 is mainly located outside of the cell. The successful detection of V1 
in western blot via V1-isolation out of the culture medium and the extraction of protein 
throughout scraping off of the cell layer confirmed its predominant role as a linking 
protein on the outside of the cells. The assumption of a pericellular sheath formed by 
cancer cells consisting of CD44 and hyaluronic acid/versican aggregates could 
possibly be confirmed as a result.111 The localization of V1 on the cell surface und 
connection site enhances its function in cell–cell interaction as ECM protein involved 
in migration and adhesive processes in glioma cells. 
In light of the different expression patterns of V2 on the PCR level, the question of 
the exact localization of versican isoform V2 in or around the cell gains in importance.  
V3 cannot be detected on the protein level, as no suitable antibody is available at this 
time.  
The procession of versican isoforms by ADAMTS (A disintegrin and metalloprotease 
domain with thrompospondin motifs) proteases and other matrix-degrading metallo-
enzymes have been discussed as an explanation for difficulties in the protein 
isolation in western blot and protein detection in immunostaining.112 It has been 
shown that versican V0, V1 and V2 are cleaved by different proteases in vitro.113 
Further previous results suggest that versican V2 is present as multiple C-terminally 
truncated forms in normal brain tissue, with the full-length isoform apparently 
representing a quantitatively minor proportion of the total.114 Since ADAMTS4 
cleaves the Glu405–Gln406 bond of brain versican V2, it is possible that this 
enzyme, as well as ADAMTS 1, 5 or 9, may play an important role in the processing 
of this molecule.115 We propose that processing versican isoforms leads to the failure 
of antibody binding. 
SiRNA transfection was able to silence versican isoforms, which I was able to prove 
at the PCR and protein level. In sum, the transfection efficiency of glioma cell lines is 
pretty high and varies between 70% and 80%. Control groups in all experiments 
consisted of cells incubated with Lipofectamine only, cells transfected with a control-
siRNA, native cells and untreated cells. These control groups were needed to 
establish whether changes in cell behaviour, especially in functional assays, are side 
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effects of the transfection procedure or can be regarded as specific effects of the 
siRNA.  
The product V1 shows a clear down-regulation on the PCR level. Within the first 
three days after transfection, near-complete suppression occurred (Figure 23, figure 
24). The down-regulation of V1 was seen at least until days 4-5 after transfection. 
Following that, the expression of V1 returned to its initial value as measured by the 
signal intensity of the PCR product in gel electrophoresis. As regards similarities 
between the structure and components of versican isoforms, undesired down-
regulation of different isoforms by specific siRNA was suspected. Therefore, during 
initial testing of my siRNAs, PCRs were performed on all samples and primers 
targeting V2 and V3. I was able to show that the products showed no relevant off-
target effects when it comes to the expression of isoforms V2 and V3 in siV1-
transfected cells.  
As already reported, the expression of versican isoform V2 on the PCR level appears 
to be very inconsistent. Regarding the more or less reliable results of V2 in western 
blotting, I tried to establish functional siRNA targeting V2. The results showed that the 
down-regulation of V2 failed and resulted in the regulation of V1 and V3. This is 
probably due to the fact that there is only little scope for creation of a specific siRNA 
targeting V2 regarding the homologies in the genome between V1, V2 and V3. 
Preserving the specific of a siRNA targeting V2 goes to the expense of their 
functionality, because not all criteria can be considered for a proper siRNA design. 
The transfection with siRNA targeting V3 showed a complete down-regulation of V3 
expression on the PCR level. As there is no antibody that detects V3, siRNA 
functionality was only proven on the PCR level, whereas possible off-target effects on 
the expression of V1 and V2 were additionally ruled out on the protein level. As 
regards the results of semi-quantitative PCR, V1 regulation was observed in siV3-
transfected cells. Suggesting that V3 might play an opposite role in glioma cells than 
V1, I decided to run functional experiments to see whether the leakage of V1 and V3 
outweighs the functional ability of the cells compared to single down-regulation of V1.  
After successful transfection and down-regulation of versican isoforms V1 and V3, 
functional assays with siRNA-transfected cells were started. The selection of possible 
functional assays is dependent on the time limit, which is determined by the short-
term effect of siRNA transfection in the cell. As I was able to show that the regulatory 
effect lasts at least four days, there was sufficient time for migratory assays like the 
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Boyden chamber assay and the scratch assay. Account must be taken of the fact 
that, so far, we do not have a full understanding of which side effects occur on 
account of the simple presence of siRNA inside the cell. For example, siRNA 
mediates the expression of double-strand protein kinases (PKR), which results in the 
up-regulation of interferon-expressing genes.116 Changes in the migratory, 
proliferative and adhesive ability of transfected cells might also result from molecular 
changes mediated by the presence of a siRNA inside the cell. Therefore, the control 
groups in my experiments consisted of Lipofectamine-treated cells, control siRNA-
transfected cells und untreated cells. 
Cell proliferation assays were performed as described in the above to distinguish 
migratory effects from proliferative effects, as migration might be mimicked by severe 
proliferation. As I knew that the down-regulation of V1 lasts up to four days after 
transfection, proliferation assays were performed for up to six days to see whether 
cell motility is affected longer than the siRNA effect is seen on the PCR level. The 
experiments showed a decline in the cell number one day after seeding for all 
investigated groups, which was interpreted as being related to the previous 
harvesting, cell counting and transfection procedure. As shown in the above, the 
proliferation rate of siV1-transfected cells showed a proliferation stop within the first 
three days after transfection. In PCR, which was performed simultaneously with the 
samples of the run, regulatory effects of siRNA expired within these three days. On 
day 4, siV1-transfected cells started to proliferate less than the control groups. In the 
experiments, V3-transfected cells did not show any changes in their proliferation 
behaviour compared with the control groups.  
It has been reported that versican is highly expressed in developing tissue where 
cells are metabolically active and proliferating.117 It has also been shown that 
versican expression is elevated in brain tumour tissue compared to the surrounding 
normal tissue. Older papers have described that the increased proliferation rate in 
tumour cells depends on the G3 domain of versican.118 It has been shown that the 
proliferation rate of U87 cells could be enhanced by adding a G3-domain-containing 
medium to the cell culture.119 In another work, the G1-domain of versican appeared 
to be relevant for increased proliferation rates in fibroblasts.120 Further, tumour 
growth, proliferation and angiogenesis can be enhanced by over-expression of the 
G3-domain in astrocytoma cancer cells.121 As the G1- and G3-domain are part of 
each splice variant of versican, I intended to investigate whether the different 
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isoforms V1, V2 and V3 containing G3-domains have a similar or a distinct influence 
on proliferation rates in glioma cell lines. 
My results suggest that V1 seems very important in the modulation of proliferation of 
malignant glioma cells. It is still not fully understood which components interact with 
versican isoform V1 in glioma cell lines and enhance the proliferation rate. 
Transferring data from other work on different cell populations, growth factor 
interaction might play a key role. It was shown that components like EGF-like motifs 
in the G3-domain of versican activate EGF-receptors.122 This mechanism was 
interpreted as an indicator of increased proliferation rate in endothelial cells.123 I 
hypothesize that the impaired proliferation rate under V1 down-regulation might result 
from the loss of complexes between G3-domains of V1 and other cellular and 
extracellular components, like growth factor receptors. In sum, my results 
reconfirmed these observations, which were already made in NIH-3T3 and 
astrocytoma cells in vivo.124,125 My results showed that V1 is essential for proliferation 
in high-grade glioma cell lines in vitro. 
No data are yet available on the influence of V3 on the proliferation rate in glioma cell 
lines. Diverse effects of V3 in different cell populations have been described in the 
literature. V3 reduces cell growth in vivo and in vitro and promotes metastasis in 
melanoma cancer cells.126 Given that siV3 transfection leads to co-regulation of V1 
and V3, I expected a stable and an increasing proliferation rate, respectively. My 
experiments showed that under siV3 transfection, the proliferation rate remained 
stable. Consequently, Iwe suggested that V3 negates the adverse effect of V1, 
meaning V3 tends to lower the proliferation rate in glioma cell lines.  
Diffuse invasion of glioma cells is a limiting factor in brain tumour survival. 
Detachment and migration has been described as a very complex combination of 
processes, including modulation of the ECM, proteinase activity and interaction 
between cell surface and extracellular matrix.127 Changes in the synthesis, 
degradation and modification of matrix adhesion molecules, as well as those of their 
receptors have been shown to be involved in various aspects of malignant cancer 
cell behaviour.128 Cell migration is mediated by the complex interplay of detachment, 
adhesion and motility that involves a number of different proteases and other 
enzymes. Because of the close connection of cellular processes in cell adhesion and 
migration, I will discuss my results of attachment and migration assays together.  
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Before starting the attachment experiments with transfected cells, the optimal time 
point for adhesion after seeding was determined for each cell line used. The 
experiments were performed as described in the above. Interestingly, no significant 
changes in the adhesive behaviour of siV1- and siV3-transfected cells were observed 
compared to the control groups in all the cell lines investigated. The adhesive 
potential was further checked at different times in each cell line. Here, the adhesive 
ability of si-control, siV1- and siV3-transfected cells was slightly increased at early 
time points compared to native cells in the cell lines A172 and HTZ419 (Figure 43, 
Figure 45). As this phenomenon was observed in si-control transfected as well as in 
cells transfected with a target-siRNA, it could be interpreted as an effect of the 
transfection procedure. However, no statistical significance is available to confirm 
that impression.  
The G1-domain of versican is able to reduce cell adhesion in glioma cells129. Some 
publications have shown that in glioma cells, the G3-fragment of versican contains 
EGF-like motifs and ß1-integrin. All of these components are able to bind to U87 and 
enhance cell attachment.130 On the other hand, in osteosarcoma cells, it has been 
shown that versican acts as an anti-adhesive molecule.131 These findings contradict 
observations from melanoma cells, where V3 increases cell adhesion on hyaluronic 
acid.132 In view of the results of this work, it can be said that selective down-
regulation of V1 and V3 in different glioma cell lines does not affect the adhesive 
behaviour in these cells in a statistically significant manner. The adhesive potential of 
glioma cells seems to be related to the G3-domain of the versican isoforms, which 
could not be proven in our experiments. As V1 and V3 contain both a G1- and a G3-
domain, it can be suggested that within intracellular modification (i.e. 
phosphorylation), these domains exist in active and non-active forms. 
Migratory ability is also facilitated by the fact that versican-rich ECMs exert an anti-
adhesive effect on tumour cells133. Versican shows anti-adhesive effects in tumour 
cells, which enables cells to migrate and proliferate. Besides EGFR, tenascin, CD44, 
integrins and hyaluronan, TGF-ß2 was identified as an interaction partner of versican 
isoform V1 during migration. Our group has already shown that TGF-ß2 induces 
migration of glioma cells.134 After adding TGF-ß2, versican isoforms V0 and V1 were 
unregulated, resulting in significantly higher migration rates compared to the 
untreated controls.135 The scratch assay was used for two-dimensional analyses of 
directional migration. The Boyden chamber assay was additionally performed to 
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gather more information on the migration behaviour of transfected glioma cells in a 
three-dimensional setting. 
The transfection procedure itself diminishes the migration rate in all investigated cell 
lines compared to the untreated, native cell population. The results of siV1-
transfected cells were therefore compared to the results of the si-control transfected 
cell population. SiV1-transfected cells showed significantly lower migration rates than 
control groups in all investigated cell lines in the scratch assay. Certainly, account 
needs to be taken of the fact that the results in the two-dimensional migratory scratch 
assay were influenced by different factors, i.e. the cell-cell interaction and cell 
proliferation. During the 36 hours the experiment ran, cells passed through a 
complete cell cycle, so the gap in the scratch assay was likely to be closed by 
proliferating cells. My results showed that cell proliferation was diminished in siV1-
transfected cells in a statistically significant manner compared to the control groups.  
Thus, migration ability needs to be investigated separately from the influence of 
proliferation and cell–cell interaction. The Boyden chamber assay was established for 
this purpose, and clearly confirmed the results of the scratch assays. SiV1-
transfected cells migrated significantly less than cells in the control groups. Based on 
my results, I suggest that versican isoform V1 is a very important component in the 
migratory process of malignant glioma cells. 
Investigating the role of V3 in migration assays, my results showed that siV3-
transfected cells did slightly increase in their migration ability, but statistical analysis 
did not prove the results to be statistically significant. Still considering that siV3 
transfection also has a down-regulatory effect on V1 expression, the inhibiting effect 
of siV1 on migration ability in glioma cell lines can be interpreted as being 
counteracted by an adverse effect of siV3. An additional effect of versican isoform V1 
and V3 in migratory processes can definitively be ruled out. 
In summary, my results demonstrate the predominant role of versican isoform V1 in 
regard to the migration and proliferation ability of malignant glioma cell lines. The 
importance of versican isoforms V1 and V3 was illuminated in different functional 
assays. As the effect of siRNA lasted at least three to four days, time appeared to be 
a limiting factor in my experiments. The internal control of counter-regulation 
mechanisms during transfection is currently done using primers and antibodies 
targeting V1, V2 and V3, respectively.  
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For further long-term experiments, a short hairpin vector system was established for 
stable transfection in glioma cells. This tool offers many opportunities, for example 
the investigation of cells in a long-lasting functional experiment and transfer of the 
vector systems in vivo. I was able to show a clear down-regulation of versican 
isoform V1 in the cells that were transfected with a short hairpin vector targeting V1. 
Results were confirmed on the RNA level and in western blots.  
Future in vivo experiments may help to detect physiological changes in a living 
organism throughout transfection, which is not accessible in in vitro experiments. In 
the nude mice model, inoculation of shV1-transfected glioma cells would offer the 
opportunity to analyse cell invasion via live-cell imaging. It will be interesting to see 
whether  in vitro assays are reproducible in vivo. Moreover, toxicity in living animals 
needs to be examined.  
Some further questions could be addressed by means of in vivo experiments. On the 
one hand, it will be necessary to elucidate whether cells develop counter-regulation 
mechanisms to cover the function of down-regulated molecules. Further, it will be 
interesting to elucidate which signalling pathways are involved, which could shed 
light on other possibly important molecules. Further, it will be of great interest to see 
whether versican isoform V1 has interfaces with known important molecules (e.g. 
p53, PTEN, EGFR, CDKN2A/2B and NF1136) and pathways and whether its role in 
regard to tumour migration and proliferation is reconfirmed in vivo.  
The stem cell model in tumour genesis has recently been gaining in importance. The 
underlying cancer stem cell hypothesis postulates that malignancies are maintained 
by a rare subpopulation of stem cell-like cells deriving from the cell of origin of a 
given tumour.137 As the origin and characteristics of these cells are still not fully 
understood, the more precise scientific term, namely cancer-initiating precursors, is 
used.138 Besides findings of cancer stem cells in haematopoietic cancer, recently 
cells with stem cell-like qualities have been found in brain tumours, for example in 
high-grade glioma, ependymoma and medulloblastoma.  
Inherent differences in the sensitivity of clonogenic cells are hypothesized as an 
explanation for clinical drug failure, tumour heterogeneity and age-response 
relationships.139 The capacity to culture brain tumour stem cells in vitro could give us 
the opportunity to devise new and more specific therapeutic approaches to targeting 
incurable brain tumours. 
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Knowing about the role of versican in the fate of embryonic stem cells and its role in 
glioma cell lines in vitro, it would be interesting to investigate the role of versican and 
its isoforms in glioma stem cells as a possible target for tumour therapy. 
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